US20010033867A1 - Systems and methods for local delivery of an agent - Google Patents
Systems and methods for local delivery of an agent Download PDFInfo
- Publication number
- US20010033867A1 US20010033867A1 US09/888,757 US88875701A US2001033867A1 US 20010033867 A1 US20010033867 A1 US 20010033867A1 US 88875701 A US88875701 A US 88875701A US 2001033867 A1 US2001033867 A1 US 2001033867A1
- Authority
- US
- United States
- Prior art keywords
- therapeutic agent
- catheter
- distal end
- delivering
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
- A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
- A61B2018/00392—Transmyocardial revascularisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
- A61M2025/0089—Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
- A61M2025/0089—Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
- A61M2025/0091—Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip the single injection needle being fixed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/12—Blood circulatory system
- A61M2210/125—Heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
- A61M25/0133—Tip steering devices
Definitions
- the invention relates to the local delivery of therapeutic agents, and more particularly, to systems and methods that deliver depots of therapeutic agents into a body of tissue to allow for the treatment of a variety of conditions, including coronary conditions and cardiovascular indications.
- angioplasty a procedure in which a balloon is inserted into the vessel and then inflated to dilate the area of narrowing. During inflation, the balloon can damage the vessel wall. It appears that as a result of this damage, in 30 to 50% of cases, the initial increase in lumen dimensions is followed by a localized re-narrowing (restenosis) of the vessel over a time of three to six months.
- restenosis a localized re-narrowing
- restenosis can result in the dangerous and localized renarrowing of a patient's vessel at the site of the recent angioplasty.
- restenosis is complex and at present there is no clinically effective treatment for this disease. Gibbons et al, Molecular Therapies for Vascular Diseases , Science vol. 272, pages 617-780 (May 1996).
- systems that attempt to achieve localized delivery of therapeutic agents. These systems include dual balloon delivery systems that have proximal and distal balloons that are simultaneously inflated to isolate a treatment space within an arterial lumen.
- a catheter extends between the two balloons and includes a port that can admit within the treatment space between the balloons an aqueous medium, typically one containing a therapeutic agent. Pressure can be applied to the medium to create conditions conducive to intramural infusion.
- Other balloon-based localized delivery systems include porous balloon systems, hydrogel-coated balloons and porous balloons that have an interior metallic stent.
- Other systems include locally placed drug-loaded coated metallic stents and drug-filled polymer stents. Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries , Trend Cardiovasc Med, vol. 3 (1993).
- an object of the invention to provide methods of treatment of a coronary artery or cardiac indication that provide a longer duration of drug pendency at the site of a localized disease.
- the invention provides systems and methods for implanting a depot into a tissue wall to thereby deliver a therapeutic agent selected for the condition being treated.
- the invention provides systems and methods for delivering a therapeutic agent into the myocardial tissue wall for treating various vascular conditions including restenosis, ischemic tissue, and myocardial infarction.
- Other applications of the systems and methods described herein include the delivery of angiogenesis compounds that can be implanted into ischemic tissue; and/or antiarrhythmic drugs that can be implanted at the sites of conduction abnormalities.
- agent being locally delivered can depend on the application at hand, and the term agent, or therapeutic agent, as employed herein will be understood to encompass any agent capable of being locally delivered including, but not limited to, pharmaceutical compositions or formulations, viral or non-viral vectors (e.g., adenovirus vectors, retroviral vectors and the like), implantable (genetically engineered) cells, plasmid-liposome complexes or other DNA delivery complexes, oligonucleotides or any other suitable composition compatible with the subject being treated.
- pharmaceutical compositions or formulations e.g., adenovirus vectors, retroviral vectors and the like
- implantable (genetically engineered) cells e.g., adenovirus vectors, retroviral vectors and the like
- plasmid-liposome complexes or other DNA delivery complexes oligonucleotides or any other suitable composition compatible with the subject being treated.
- the invention is understood as apparatus for delivering therapeutic agents, comprising an elongate flexible body having a proximal end and a distal end, a delivery chamber coupled to the distal end of the body and having a space for carrying the therapeutic agent, and a port for releasing the therapeutic agent therefrom.
- the apparatus further includes an actuator coupled to the distal delivery chamber and being capable of driving therapeutic agent through the port.
- proximal and distal as used herein will be understood to describe opposite ends of a device or element, and generally will be employed so that proximal is understood as “away from the heart” and distal is understood as “towards the heart” or to mean “toward the physician” and “away from the physician” respectively.
- the apparatus further includes a control mechanism that couples to the actuator and to the proximal end of the body for providing control of the actuator. In this way a user can operate the control mechanism for selectable delivery of the agent.
- the apparatus can also include a “steering” mechanism for bending the distal end of the body to thereby allow the delivery chamber to be selectively aimed or directed within the chambers of the heart.
- the distal end of the flexible body can be dimensionally adapted to allow for transluminal delivery and for entry into the interior of a patient's heart.
- the distal end of the apparatus which carries the delivery chamber, to travel through the patient's vasculature, enter the patient's heart, and butt against or penetrate through the endocardial tissue and penetrate into the myocardium.
- the distal end of the delivery chamber can be further provided with a pointed distal end which is adapted to penetrate a tissue wall for delivering the therapeutic agent into the tissue wall.
- the apparatus can further include a plunger for driving a therapeutic agent from the delivery chamber.
- the plunger can include a ratchet assembly for allowing the delivery of discrete volumes of therapeutic agent, or a discreet number of pellets containing a therapeutic agent.
- the plunger can be provided with a threaded assembly and worm gear assembly for rotatably advancing the plunger into the delivery chamber responsive to a rotating action.
- an actuator such as a plunger disposed within the delivery chamber can act on pellets of therapeutic agents stored within the delivery chamber to force the pellets from the delivery chamber and implant them within a tissue wall.
- a delivery chamber can be dimensioned to receive one or a plurality of pellets containing a therapeutic agent.
- the activation of the plunger or actuator can be by manipulation of a lever action handle mounted at the proximal end of the flexible body and coupled to the control mechanism.
- a rotary mechanism optionally motorized, can be provided for rotating a threaded plunger to advance the plunger within the delivery chamber thereby forcing pellets of therapeutic agent from the chamber.
- a mechanism for receiving at least one pellet containing the therapeutic agent and having a pointed shape for facilitating implanting the pellet within a body of tissue.
- a plunger can be provided for forcing the pointed pellet from the delivery chamber and implanting the pellet within a tissue wall of the patient, such as within the myocardium.
- the invention can be understood as pellets adapted for carrying a therapeutic agent into the tissue wall of a patient.
- the pellets include a radio-opaque marker typically located at the core of the pellet which facilitates the fluoroscopic viewing of the delivery of the pellets.
- the invention can be understood as methods for providing local delivery of a therapeutic agent which include the step of implanting the therapeutic agent into a portion of myocardial tissue.
- the methods include the step of providing a catheter having a distal end adapted for delivering the therapeutic agent, guiding the catheter into the interior of a patient's heart and disposing the distal end of the catheter against an endocardial wall of the heart for implanting the therapeutic agent into the myocardial tissue.
- the step of providing a catheter can include the step of providing a steerable catheter which, optionally, can include a drilling element for penetrating a tissue wall such as the endocardium.
- a plurality of pellets containing a therapeutic agent, or a plurality of therapeutic agents are delivered sequentially into the myocardial tissue.
- each pellet can contain a therapeutic agent and a radio-opaque marker.
- the local delivery of the therapeutic agent is accomplished by transluminal delivery in which the catheter is steered through access at the femoral artery or vein and directed into the heart.
- a marker can be positioned in a selected portion of a coronary artery to identify a location for receiving the therapeutic agent.
- the marker can be observed fluoroscopically during the procedure, and a treating physician can use the positioned marker for targeting the location of the myocardium into which the therapeutic agent is to be implanted.
- the procedure includes a step of endoscopically delivering the therapeutic agent through the epicardium.
- the therapeutic agent is implanted into the myocardial tissue during open chest surgery.
- the invention provides methods for delivering a therapeutic agent to a septal artery.
- the method comprises the steps of providing a catheter having a distal end that is adapted for delivering the therapeutic agent, guiding the catheter into the interior of a patient's heart and disposing the distal end of the catheter against a septal wall of the heart for implanting the therapeutic agent into the septal tissue.
- FIG. 1 depicts one embodiment of a catheter having a delivery chamber carried at the distal end
- FIGS. 2A and 2B depict in more detail the delivery chamber of the catheter depicted in FIG. 1;
- FIGS. 3A and 3B depict an alternative delivery chamber for use with the catheter of FIG. 1;
- FIGS. 4A and 4B depict two embodiments of pellets suitable for implantation by the catheter of FIG. 1;
- FIG. 5 depicts one method for delivering a therapeutic agent to the myocardium
- FIG. 6 provides a cross-cut perspective of a coronary artery extending through the myocardium and having pellets of therapeutic agent disposed around the artery;
- FIG. 7 depicts a local drug delivery device having a pistol grip and being suitable for use during an endoscopic procedure.
- the depot implanting systems illustrated herein include catheter systems for delivery via the chambers of the heart, endoscopic systems for pericardial approach via minimally invasive transthoracic access, and systems for use during intraoperative pericardial approach during open-chest surgery.
- the devices deliver a plurality of pellets that surround, or partially surround, an artery being treated. This is understood to achieve the effect of implanting a drug-filled ring around the artery.
- the pellets remain in the myocardial tissue, and can give off drug(s) for a selected time period and then be absorbed by the body.
- the systems described herein can implant pellets that contain radio-opaque markers to facilitate viewing the pellets by fluoroscopy during catheter delivery.
- FIG. 1 depicts one embodiment of a system for providing local delivery of a therapeutic agent.
- the delivery device 10 includes a catheter 12 , a delivery chamber 14 , steering switches 16 a and 16 b , a handle 18 , and a delivery control switch 20 .
- the depicted system 10 is a catheter system that can be guided through vascular access at the femoral artery or vein of a patient until the delivery chamber 14 enters into the interior chambers of the patient's heart to implant a depot of drug within the myocardium.
- the catheter 12 which extends between the delivery chamber 14 and the handle 18 can be approximately 175 cm to 200 cm in length and can include an elongated rotationally rigid, longitudinally flexible body optionally made of woven polyester fibers, stainless steel wires, thermoset or thermoplastic polymers or any other material suitable for use as a catheter shaft.
- the catheter can have a substantially uniform diameter of approximately 0.025 to 0.100 inches (0.62 to 2.5 mm).
- the catheter 12 is a steerable catheter that allows or facilitates the guiding of the catheter through the patient's vasculature and into the chamber of the patient's heart. Further, the steerable catheter 12 allows the physician to bend the catheter once the catheter has entered into the interior of the heart, to thereby position the delivery chamber 14 adjacent the area of the endocardial wall through which the delivery chamber is to penetrate.
- the steering capability of the catheter 12 is illustrated by the bend located at the distal end of the catheter 12 .
- Steering catheters suitable for use with the present invention are known in the art, and include steering catheters employed in Electrophysiology procedures. Electrophysiology catheters typically provide steering through a combination of rotation and tip bending.
- One suitable steerable catheter is described in U.S. Pat. No. 5,656,029, which is incorporated herein by reference.
- This catheter provides an elongate flexible body that carries a bending mechanism at its distal end.
- the bending mechanism consists of a shape-memory element typically formed of Nitinol which is provided with a memory which makes it assume a straight condition when it is heated, such as by application of an electrical current.
- the shape memory element extends through the distal portion of the catheter and is adapted to remain straight along its full length in response to a current passing through the element.
- an electrical bypass is slidably mounted about the bending element.
- the bypass element can be an elongate cylindrical sleeve formed of a conductive material and through which the bending element can extend.
- the bypass element can act as a short circuit that bypasses current away from the bending element. Accordingly, the bypass element prevents current from heating the bending element at the location of the bypass. Consequently, the bending element will bend at the location of the bypass.
- the physician can select the location of the bypass, thereby selecting the location of bending. As the delivery chamber 14 is carried at the distal extremity of the catheter 12 , this allows the physician to selectively position the delivery chamber 14 within the interior of the patient's heart.
- bending elements and bypass elements described above are carried within the catheter 12 and are not shown in FIG. 1, but however are described in detail in the above identified reference. Additionally, it is noted that although the catheter 12 has been described with reference to one type of steerable catheter it will be apparent to one of ordinary skill in the art that other suitable steering mechanisms can be employed with the present invention including steering mechanisms that include actuating poles or wires that extend longitudinally through the catheter body. Moreover, it will be further understood that although the depicted catheter 12 is optionally a steerable catheter, the devices of the invention are not to be limited to steerable devices, and will be understood to encompass conventional catheter systems as well.
- Control of the depicted catheter 12 and the delivery chamber 14 is provided by the integrated hand-held control mechanism and handle 18 mounted on the proximal end of the catheter 12 .
- the control mechanism/handle 18 can be of various types, and the depicted handle 18 is adapted for operating a steerable catheter wherein the bend of the catheter can be selectively controlled by the physician.
- the hand-held control/handle 18 is dimensionally adapted to provide the treating physician with a device that is facile to manipulate and comfortable to hold.
- the hand-held mechanism/handle 18 includes a set of control switches, 16 a , 16 b and 20 that allow the physician to control the steering of the catheter 12 and the implanting of the depot.
- Switches 16 a and 16 b can provide steering control for the catheter 12 .
- the switch 16 a can be a slidable switch that allows the physician to control the longitudinal position of the bend within the distal tip of the catheter.
- the switch 16 a can activate the bending mechanism to cause the catheter tip to bend as needed.
- the control switch 20 can activate the delivery chamber 14 to cause a pellet containing a therapeutic agent to be delivered into a tissue wall.
- control mechanisms/handles can be employed with the systems of the invention without departing from the scope thereof Specifically, other systems can include joystick controls for operating the steerable catheters and can include controls for rotating the angle at which the distal end of the catheter bends. Still other control mechanisms/handles can include pistol grips for providing manual activation of the delivery chamber 14 . Other modifications and additions can be made to the control mechanism/handle without departing from the scope of the invention.
- FIG. 2A depicts in greater detail one delivery chamber 14 which is suitable for being carried at the distal end of the catheter 12 depicted in FIG. 1.
- the delivery chamber 14 is sized to hold the plurality of minispheres 22 , each of which contains a therapeutic agent.
- the minispheres 22 are carried within an interior chamber 24 which is bound at the proximal end by a plunger 33 and bound at the distal end by a wall formed of a plurality of flexible finger elements 36 that define a port 30 .
- an optional detent 34 is connected to a sidewall of the chamber 24 to provide a mechanical stop that prevents the minispheres 22 from freely exiting through the port 30 .
- the minispheres 22 can be pushed over the detent 34 , for allowing one minisphere 22 to be ejected through port 30 .
- the plunger 33 depicted in FIG. 2A includes a plate 38 and an actuating rod 40 .
- the plate 38 is dimensioned to fill substantially the diameter of interior chamber 24 to provide thereby a surface that is adapted for forcing the minispheres 22 through the chamber 24 and out of port 30 .
- the actuating rod 40 is connected to the plate 38 and provides a mechanical force to plate 38 to advance, or drive, the plate 38 distally into the chamber 24 .
- the actuating rod 40 extends through the catheter 12 and couples to the control mechanism/handle 18 at the proximal end of device 10 .
- the control mechanism/handle 18 includes a mechanism that drives the actuating rod 40 distally causing minispheres 22 to be delivered through port 30 .
- this embodiment can include a control mechanism/handle 18 that incorporates a ratchet assembly that drives the actuating rod 40 distally in discreet steps wherein a predetermined number of steps corresponds substantially to the diameter of one of the minispheres 22 .
- the depicted control switch 20 can be a rotatable switch that allows for manual actuation of a ratchet assembly contained within the control mechanism/handle 18 .
- the ratchet assembly allows the physician to drive the plunger 33 distally into the chamber 24 thereby driving the minisphere 22 out of the port 30 . In this way, the device 10 can allow for the discreet and sequential delivery of minispheres 22 from the delivery chamber 14 .
- the plunger 33 is threaded to mate with a threaded interior portion of chamber 24 .
- Manual or motor-driven rotation of actuating rod 40 will advance or retract the plunger with a finer degree of control than that provided by strictly linear actuation.
- Such control over the travel distance of the plunger 33 into and out of the interior chamber 24 gives control over the number of minispheres 22 delivered through port 30 .
- FIG. 2B provides a head-on perspective of the delivery chamber 14 , showing the distal most portion of the delivery chamber 14 as viewed from a position along the longitudinal axis of the delivery chamber 14 .
- FIGS. 2A and 2B show that the distal end of the delivery chamber 14 includes a port 30 that is formed from the convergence of a plurality of flexible arched fingers 36 , each of which is formed from a resilient material and each of which is biased to hold the minispheres 22 within the interior chamber 24 .
- the fingers 36 Upon action of the plunger 33 to move the minispheres 22 distally, the fingers 36 will yield to the axial pressure and release a minisphere 22 .
- the optional detent 34 provides further resistance that prevents minispheres 22 from exiting chamber 24 through the port 30 and for providing a tactile sensation that indicates when a minisphere 22 has been released, or has become available to be released, through port 30 .
- the delivery chamber 14 is adapted to facilitate the implantation of a depot of drug within a tissue wall.
- the delivery chamber 14 can be sized and made of a material rigid enough to facilitate the penetration of the delivery chamber within a tissue wall.
- the depicted delivery chamber 14 can be about 0.010 to 0.050 inches in diameter, and about 0.05 to 0.075 inches in length, to have a needle-like profile that is suitable for penetrating tissue.
- the depicted delivery chamber 14 can be formed of stainless steel or of plastic material that is sufficiently rigid to allow the delivery chamber 14 to pass into a tissue wall.
- FIGS. 3A and 3B depict an alternative embodiment of a delivery chamber suitable for use with the catheter system 10 shown in FIG. 1.
- the depicted delivery chamber 50 includes a cylindrical sidewall 58 that defines an interior space that houses a plunger 52 .
- the plunger 52 includes a grooved plate 62 that can be rotatably driven along the threads 64 that extend along a portion of the sidewall 58 . Accordingly, in this embodiment, the plunger 52 advances into the delivery chamber 50 as the plate 62 turns across, and travels over the threads 64 .
- the distal end of the plunger 52 butts against a stack of nested drug delivery pellets 60 and forces the pellets 60 against the elongate flexible finger elements 54 that, as shown by FIG. 3B, define the port 56 .
- the delivery chamber 50 implants drug pellets having a hollow, conical shape which facilitates the penetration of the implants 60 into the tissue wall.
- the plunger 52 can drive the pellets 60 through the port 56 and into the tissue wall.
- the flexible fingers 54 are biased to hold the pellets 60 within the chamber 50 , however, the mechanical force applied by the plunger 52 will be sufficient to overcome the bias force of the fingers 54 .
- a ratchet assembly, a rotary actuator, and/or optionally a detent can be employed to help the physician control the number of pellets being delivered into the tissue wall.
- the ratchet assembly or rotary actuator controls the distance the plunger 52 is driven into the chamber 50 and the detent provides a tactile sensation each time a pellet 60 is moved a predetermined distance.
- the delivery chamber 50 provides an alternative embodiment that allows for the implantation of larger pellets of drugs where the size of the pellet may require a delivery chamber that is too large to readily penetrate through a tissue wall. Accordingly, delivery chambers can be selectively developed for the implantation systems described herein based on the applications of interest and the size of the pellet being delivered. For example, in systems that implant microspheres of drugs having diameters of about 5-15 ⁇ m, the delivery chamber can be adapted to hold the microspheres in a fluid medium and a plunger assembly, or other suitable system, can be employed to flush the microspheres from the delivery chamber and into the tissue wall.
- the delivery chamber can be simply a hypodermic needle, and a syringe connected to the proximal end of the system can inject the fluid medium through a lumen in the catheter 12 .
- Other delivery chambers can be employed with the systems described herein without departing from the scope hereof.
- the systems described above are capable of implanting pellets that contain a therapeutic agent.
- the therapeutic agent can be any compound that is biologically active and suitable for long term administration to a tissue or organ.
- the pellets described above can be formed as mini-spheres that are on the order of about 0.005 inches to about 0.040 inches in diameter. Particles of this size are capable of providing a therapeutically effective dose of agent and can remain where implanted, resisting fluid flux through the tissue wall.
- pellets capable of acting as drug delivery implants are well known in the art.
- a solid pellet is formed from a biodegradable polymer that has been doped or “seeded” with the desired therapeutic agent.
- the polymer is a synthetic polymer, such as poly(lactic acid) or polyorthoesters, and is formed by solvent evaporation, spray drying, or phase separation.
- Such a pellet 70 is depicted in FIG. 4A.
- the polymer is capable of breaking down over time, allowing the drug to be released into the adjacent tissue.
- a sphere of a precious metal such as gold or platinum
- the drug-filled polymer 72 can be covered with the drug-filled polymer 72 in a thickness that provides the desired volume, dosage and/or time release profile.
- Other acceptable drug delivery implants include the “container” implant which is filled with a liquid drug.
- a wall of the container is at least partially made of a biodegradable polymer that permits passage of drug molecules at a certain rate. This design is common for injectable microspheres.
- One advantage is that it can work for drugs that are not amenable to doping in polymers because of heat processes or other incompatibilities.
- a radioopaque metal core could be incorporated into this “container” type pellet to facilitate viewing.
- pellets delivered into or against the tissue wall can be coated with or include adhesive materials that adhere to tissue. Further, coatings can be provided that facilitate the absorption of the pellet into the tissue wall. Such coatings can include fumaric acid, sebacic acid and other similar materials.
- FIG. 4B depicts in more detail a pellet 76 suitable for delivery by the delivery chamber 50 depicted in FIGS. 3A and 3B.
- the pellet 76 is a hollow conical body that provides a pointed end that facilitates delivery of the pellet 76 into a tissue wall.
- the pellet 76 can carry a radio opaque marker (not shown) and, in one embodiment, the radio opaque marker comprises grains of a noble metal which are incorporated into the material of which the pellet 76 is formed.
- FIGS. 5 and 6 depict more explicitly one method according to the invention for implanting a therapeutic agent into a tissue wall.
- the depicted method is a cardiovascular treatment for restenosis that can occur in a coronary artery.
- the method includes the steps of employing an elongate flexible surgical instrument (e.g., a catheter) having a distal end that carries a delivery chamber 14 .
- the distal end is inserted into a vascular system of a patient, such as by insertion via a femoral artery or vein.
- the delivery chamber 14 is guided through the patient's vascular system until the delivery chamber 14 is disposed within the heart, such as within the left ventricle. Once within the heart, the delivery chamber is employed to implant a therapeutic agent into the tissue of the heart.
- the physician can determine the therapeutic agent, or agents, to be implanted and the depot for the selected agents.
- the depot may be selected by considering, inter alia, the desired time of drug residence within the tissue and the desired dosage to be eluted during the course of the residence.
- the pellets can carry a plurality of therapeutic agents, either by solidifying a plurality of agents within the polymer coating of each pellet, or by providing pellets carrying different therapeutic agents. This latter practice allows the physician to load both active therapeutic agents and agents capable of activating therapeutic agents upon contact, or capable of degrading the polymer wall of an implanted pellet. This can allow for greater time delay before activation of an agent, and for greater selection in the delivery vehicle and the agents and drugs being delivered.
- the physician can select the delivery chamber to use and can pre-load the delivery chamber with a plurality of pellets, each of which can be a minisphere, a helical, conical pellet, a cylindrical container, or other device capable of being implanted into the myocardium.
- the physician can preload the delivery chamber 14 with the set of pellets that have been selected to deliver the proper depot of therapeutic agent to the tissue around an artery that is suffering from, or may suffer from, restentosis.
- pellets containing a desired therapeutic agent can be preloaded into the delivery system, which is provided to the physician as a sterile, disposable item.
- the treating physician Before delivering the preloaded delivery chamber 14 into the heart, the treating physician optionally performs a preliminary step of positioning a radio-opaque marker at the site of restenosis. This allows the treating physician to view the marker during delivery of the pellets.
- the marker can be a stent, or any viewable marker that will remain present at the site of the localized disease during the implanting of the drug delivery pellets.
- the marker can be the radio-opaque marker of a balloon being employed during a PTCA procedure.
- a PTCA procedure Specifically, as restenosis may arise from the site of the angioplasty, one practice of the invention performs the drug delivery at the same time as the angioplasty. In this procedure, the treating physician leaves the PTCA catheter in place, while the delivery implant system is guided to the target area. A radiopaque marker in the balloon gives fluoroscopic guidance during the implant procedure.
- the physician can guide the implant system along the appropriate delivery route until the catheter enters the interior of the patient's heart.
- the delivery chamber can approach target areas from within any chamber of the heart. Notably, the practices described herein allow that even septal arteries can be treated for cardiac conditions or to stimulate angiogenisis.
- the delivery chamber is shown as approaching the target area from the interior of the heart, and positioning the delivery chamber against the endocardial tissue over the myocardium.
- the physician drives the delivery chamber into the tissue and to the targeted area.
- the physician actuates the control mechanism and ejects a pellet from the delivery chamber, implanting the pellet within the targeted area of the myocardium.
- FIG. 6 illustrates a further realization of the present invention.
- FIG. 6 shows that it is desirable to implant the pellets as close as possible to the artery being treated, and that providing an array of implanted pellets about the periphery of the artery may provide sufficient localized elution of therapeutic agent to prevent restenosis.
- the pellets are implanted through a single point of entry through the myocardium. The physician manipulates the distal tip of the catheter to dispose the port of the delivery chamber at the depicted locations. At each location, a pellet is ejected from the delivery chamber and implanted into the myocardium.
- FIG. 7 depicts a further alternative embodiment of the invention.
- the depicted system 80 includes a short catheter 82 that carries a delivery chamber 84 at its distal end and that connects at its proximal end to a pistol grip control mechanism 88 .
- the system 80 is adapted for use during an endoscopic procedure and to that end the depicted catheter 84 is a short catheter adapted to slide within a endoscopic port that has been placed through the chest and positioned abutting the pericardium.
- the delivery chamber 84 can be a delivery chamber as discussed above and can be dimensionally adapted to penetrate and extend through the pericardial sac. The delivery chamber can penetrate into the myocardium and thereby allow the physician to implant pellets into the myocardium.
- the catheter 82 can be a steerable catheter which allows the physician to bend the distal tip of the catheter 82 to place the delivery chamber 84 where needed.
- the catheter can include a deflectable tip, as is known in the art, which the physician can direct to the targeted area.
- a deflectable tip as is known in the art, which the physician can direct to the targeted area.
- Other modifications to the system 80 including providing the catheter with a fiber optic viewing device to allow the physician to view the interior of the pericardial sac, can be made without departing from the scope of the invention.
- the depicted pistol grip 88 provides the physician with a manual actuator that allows the physician to control the implanting of pellets within the myocardium.
- the pistol grip 88 can be a molded plastic assembly of the type well known in the art for actuating a mechanical assembly, such as the plunger assembly of the delivery chamber 14 described above.
- the techniques of the invention can be employed during an open chest procedure.
- the surgeon performing the open chest operation can employ a delivery device that includes a delivery chamber as described above to implant pellets into the myocardium.
- the physician can employ a hypodermic needle to inject a solution containing microspheres of a therapeutic agent.
- Other practices of the invention can be practiced without departing from the scope thereof.
- the systems and methods for implanting depots of therapeutic agents can be applied to conditions other than those relating to cardiac failure.
- the systems described herein can be applied to the treatment of muscle tissue afflicted by insufficient circulation.
- the systems described herein are employed to deliver a human angiogenic growth factor, such as VGEF, which is understood to stimulate the growth of blood vessels.
- VGEF human angiogenic growth factor
- the systems described herein can promote the survival of muscle tissue that is moribund as a result of poor circulation due to failing or occluding blood vessels.
- the devices described herein can be used in cooperation with drilling elements or laser devices capable of forming an opening in a tissue wall, such as the myocardium.
- the delivery chamber can be inserted into the preformed openings for delivering a therapeutic agent therein.
- pellets according to the invention can include threaded exterior surfaces that facilitate implanting the pellet within a tissue wall. Accordingly, it will be understood that the invention is not to be limited to the embodiments disclosed herein, but is to be understood from the following claims, which are to be interpreted as broadly as allowed under the law.
Abstract
A system and method for implanting pellets into myocardial tissue for treatment of coronary artery restenosis, ischemic heart disease, or cardiac conduction of disturbances. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic pericardial approach via minimally invasive transthoracic access, or intraoperative pericardial approach during open-chest surgery. Noncardiac tissues can also be treated.
Description
- The invention relates to the local delivery of therapeutic agents, and more particularly, to systems and methods that deliver depots of therapeutic agents into a body of tissue to allow for the treatment of a variety of conditions, including coronary conditions and cardiovascular indications.
- Disease, injury and surgery can result in localized tissue damage and morbidity. For example, the principal treatment for occlusive vascular diseases is angioplasty, a procedure in which a balloon is inserted into the vessel and then inflated to dilate the area of narrowing. During inflation, the balloon can damage the vessel wall. It appears that as a result of this damage, in 30 to 50% of cases, the initial increase in lumen dimensions is followed by a localized re-narrowing (restenosis) of the vessel over a time of three to six months. Thus, restenosis can result in the dangerous and localized renarrowing of a patient's vessel at the site of the recent angioplasty. Like many other localized diseases, restenosis is complex and at present there is no clinically effective treatment for this disease. Gibbons et al,Molecular Therapies for Vascular Diseases, Science vol. 272, pages 617-780 (May 1996).
- Restenosis, like many other localized injuries and diseases, has responded poorly to pharmacological therapies and agents. Numerous pharmacological agents have been clinically tested, and none have demonstrated an unequivocal reduction in the incidence of restenosis. However, the failure of these pharmacological therapies may arise from the systemic intolerance of the doses required to achieve local beneficial effects or in the difficulty of providing controlled administration of proper dosages over time. Accordingly, one possible reason for the failure of these therapies is that submaximal doses of pharmacological agents are being administered to avoid the serious side-effects that might result from systemic administration of the proper dosage.
- To address this problem, various researchers have proposed methods for site-specific delivery of pharmacologic and molecular therapies. These methods include the direct deposition of therapeutic agents into the arterial wall through an intravascular delivery system, systemic administration of therapeutic agents that have a specific affinity for the injured or diseased tissue, and systemic administration of inactive agents followed by local activation.
- At present, systems exist that attempt to achieve localized delivery of therapeutic agents. These systems include dual balloon delivery systems that have proximal and distal balloons that are simultaneously inflated to isolate a treatment space within an arterial lumen. A catheter extends between the two balloons and includes a port that can admit within the treatment space between the balloons an aqueous medium, typically one containing a therapeutic agent. Pressure can be applied to the medium to create conditions conducive to intramural infusion. Other balloon-based localized delivery systems include porous balloon systems, hydrogel-coated balloons and porous balloons that have an interior metallic stent. Other systems include locally placed drug-loaded coated metallic stents and drug-filled polymer stents. Wilensky et al.,Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trend Cardiovasc Med, vol. 3 (1993).
- Although these systems can provide working devices for local drug delivery, the efficacy of these devices turns on, and is limited by, a number of factors including the rate of fluid flux through the vascular wall, the residence time of the deposited agent and the local conditions and vasculature of the deposition site. Essentially, the success of these systems is limited by the amount of time that a delivered drug will stay resident locally before being carried downstream by circulating blood. Further, to the extent that these systems allow the therapeutic agent to be carried away, these systems run the risk of applying a therapeutic agent to areas of the patient's vasculature where such agents may not be beneficial. Additionally, these existing systems are limited by the amount of drug that can be delivered to the diseased site. Moreover, drug filled polymer stents have structural problems that argue against their use.
- It would be advantageous to develop other methods of treatment for patients having localized cardiovascular conditions and in particular to develop methods of treatment that reduce adverse side effects and have heightened efficacy.
- It is therefore, an object of the invention to provide methods of treatment of a coronary artery or cardiac indication that provide a longer duration of drug pendency at the site of a localized disease.
- It is a further object of the invention to provide systems and methods that reduce or eliminate the downstream flow of a locally delivered agent.
- Other objects of the invention will, in part, be obvious, and, in part, be shown from the following description of the systems and methods shown herein.
- To these ends, the invention provides systems and methods for implanting a depot into a tissue wall to thereby deliver a therapeutic agent selected for the condition being treated. In one embodiment, the invention provides systems and methods for delivering a therapeutic agent into the myocardial tissue wall for treating various vascular conditions including restenosis, ischemic tissue, and myocardial infarction. Other applications of the systems and methods described herein include the delivery of angiogenesis compounds that can be implanted into ischemic tissue; and/or antiarrhythmic drugs that can be implanted at the sites of conduction abnormalities. Accordingly, the agent being locally delivered can depend on the application at hand, and the term agent, or therapeutic agent, as employed herein will be understood to encompass any agent capable of being locally delivered including, but not limited to, pharmaceutical compositions or formulations, viral or non-viral vectors (e.g., adenovirus vectors, retroviral vectors and the like), implantable (genetically engineered) cells, plasmid-liposome complexes or other DNA delivery complexes, oligonucleotides or any other suitable composition compatible with the subject being treated.
- In one embodiment the invention is understood as apparatus for delivering therapeutic agents, comprising an elongate flexible body having a proximal end and a distal end, a delivery chamber coupled to the distal end of the body and having a space for carrying the therapeutic agent, and a port for releasing the therapeutic agent therefrom. The apparatus further includes an actuator coupled to the distal delivery chamber and being capable of driving therapeutic agent through the port.
- The terms proximal and distal as used herein will be understood to describe opposite ends of a device or element, and generally will be employed so that proximal is understood as “away from the heart” and distal is understood as “towards the heart” or to mean “toward the physician” and “away from the physician” respectively.
- In one embodiment, the apparatus further includes a control mechanism that couples to the actuator and to the proximal end of the body for providing control of the actuator. In this way a user can operate the control mechanism for selectable delivery of the agent. Optionally, the apparatus can also include a “steering” mechanism for bending the distal end of the body to thereby allow the delivery chamber to be selectively aimed or directed within the chambers of the heart. The distal end of the flexible body can be dimensionally adapted to allow for transluminal delivery and for entry into the interior of a patient's heart. This allows the distal end of the apparatus, which carries the delivery chamber, to travel through the patient's vasculature, enter the patient's heart, and butt against or penetrate through the endocardial tissue and penetrate into the myocardium. To this end, the distal end of the delivery chamber can be further provided with a pointed distal end which is adapted to penetrate a tissue wall for delivering the therapeutic agent into the tissue wall.
- In a further embodiment, the apparatus can further include a plunger for driving a therapeutic agent from the delivery chamber. The plunger can include a ratchet assembly for allowing the delivery of discrete volumes of therapeutic agent, or a discreet number of pellets containing a therapeutic agent. Alternatively, the plunger can be provided with a threaded assembly and worm gear assembly for rotatably advancing the plunger into the delivery chamber responsive to a rotating action. Accordingly, an actuator such as a plunger disposed within the delivery chamber can act on pellets of therapeutic agents stored within the delivery chamber to force the pellets from the delivery chamber and implant them within a tissue wall. Optionally a delivery chamber can be dimensioned to receive one or a plurality of pellets containing a therapeutic agent. The activation of the plunger or actuator can be by manipulation of a lever action handle mounted at the proximal end of the flexible body and coupled to the control mechanism. Alternatively, a rotary mechanism, optionally motorized, can be provided for rotating a threaded plunger to advance the plunger within the delivery chamber thereby forcing pellets of therapeutic agent from the chamber.
- In a further embodiment of the invention, a mechanism is provided for receiving at least one pellet containing the therapeutic agent and having a pointed shape for facilitating implanting the pellet within a body of tissue. As discussed above, a plunger can be provided for forcing the pointed pellet from the delivery chamber and implanting the pellet within a tissue wall of the patient, such as within the myocardium.
- In a further aspect, the invention can be understood as pellets adapted for carrying a therapeutic agent into the tissue wall of a patient. In one embodiment, the pellets include a radio-opaque marker typically located at the core of the pellet which facilitates the fluoroscopic viewing of the delivery of the pellets.
- In yet a further aspect, the invention can be understood as methods for providing local delivery of a therapeutic agent which include the step of implanting the therapeutic agent into a portion of myocardial tissue. In one practice, the methods include the step of providing a catheter having a distal end adapted for delivering the therapeutic agent, guiding the catheter into the interior of a patient's heart and disposing the distal end of the catheter against an endocardial wall of the heart for implanting the therapeutic agent into the myocardial tissue. The step of providing a catheter can include the step of providing a steerable catheter which, optionally, can include a drilling element for penetrating a tissue wall such as the endocardium. In one practice, a plurality of pellets containing a therapeutic agent, or a plurality of therapeutic agents, are delivered sequentially into the myocardial tissue. Optionally, each pellet can contain a therapeutic agent and a radio-opaque marker.
- In one practice of the invention, the local delivery of the therapeutic agent is accomplished by transluminal delivery in which the catheter is steered through access at the femoral artery or vein and directed into the heart. Optionally, a marker can be positioned in a selected portion of a coronary artery to identify a location for receiving the therapeutic agent. In this practice, the marker can be observed fluoroscopically during the procedure, and a treating physician can use the positioned marker for targeting the location of the myocardium into which the therapeutic agent is to be implanted.
- In a further practice, the procedure includes a step of endoscopically delivering the therapeutic agent through the epicardium. In yet another practice, the therapeutic agent is implanted into the myocardial tissue during open chest surgery.
- In a further aspect, the invention provides methods for delivering a therapeutic agent to a septal artery. In one practice, the method comprises the steps of providing a catheter having a distal end that is adapted for delivering the therapeutic agent, guiding the catheter into the interior of a patient's heart and disposing the distal end of the catheter against a septal wall of the heart for implanting the therapeutic agent into the septal tissue.
- The foregoing and other objects and advantages of the invention will be appreciated more fully from the following further description thereof with reference to the accompanying drawings wherein;
- FIG. 1 depicts one embodiment of a catheter having a delivery chamber carried at the distal end;
- FIGS. 2A and 2B depict in more detail the delivery chamber of the catheter depicted in FIG. 1;
- FIGS. 3A and 3B depict an alternative delivery chamber for use with the catheter of FIG. 1;
- FIGS. 4A and 4B depict two embodiments of pellets suitable for implantation by the catheter of FIG. 1;
- FIG. 5 depicts one method for delivering a therapeutic agent to the myocardium;
- FIG. 6 provides a cross-cut perspective of a coronary artery extending through the myocardium and having pellets of therapeutic agent disposed around the artery; and
- FIG. 7 depicts a local drug delivery device having a pistol grip and being suitable for use during an endoscopic procedure.
- To provide an overall understanding of the invention, the methods and devices illustrated herein are described with reference to the application of treating cardiac indications by implanting drug delivery pellets into myocardial tissue for the treatment of coronary artery restenosis, ischemic heart disease, cardiac conduction disturbances and other similar conditions. However, it will be understood that the systems and methods described herein are applicable to any condition that can benefit from the implanting of a depot of a therapeutic agent, and the invention is not to be limited to the applications illustrated herein. For example, the techniques herein are directly applicable for implanting therapeutic agents to stimulate angiogenesis.
- The depot implanting systems illustrated herein include catheter systems for delivery via the chambers of the heart, endoscopic systems for pericardial approach via minimally invasive transthoracic access, and systems for use during intraoperative pericardial approach during open-chest surgery. In one practice, the devices deliver a plurality of pellets that surround, or partially surround, an artery being treated. This is understood to achieve the effect of implanting a drug-filled ring around the artery. The pellets remain in the myocardial tissue, and can give off drug(s) for a selected time period and then be absorbed by the body. The systems described herein can implant pellets that contain radio-opaque markers to facilitate viewing the pellets by fluoroscopy during catheter delivery.
- FIG. 1 depicts one embodiment of a system for providing local delivery of a therapeutic agent. The
delivery device 10 includes acatheter 12, adelivery chamber 14, steering switches 16 a and 16 b, ahandle 18, and adelivery control switch 20. - The depicted
system 10 is a catheter system that can be guided through vascular access at the femoral artery or vein of a patient until thedelivery chamber 14 enters into the interior chambers of the patient's heart to implant a depot of drug within the myocardium. To that end, thecatheter 12 which extends between thedelivery chamber 14 and thehandle 18 can be approximately 175 cm to 200 cm in length and can include an elongated rotationally rigid, longitudinally flexible body optionally made of woven polyester fibers, stainless steel wires, thermoset or thermoplastic polymers or any other material suitable for use as a catheter shaft. The catheter can have a substantially uniform diameter of approximately 0.025 to 0.100 inches (0.62 to 2.5 mm). - In the embodiment depicted in FIG. 1, the
catheter 12 is a steerable catheter that allows or facilitates the guiding of the catheter through the patient's vasculature and into the chamber of the patient's heart. Further, thesteerable catheter 12 allows the physician to bend the catheter once the catheter has entered into the interior of the heart, to thereby position thedelivery chamber 14 adjacent the area of the endocardial wall through which the delivery chamber is to penetrate. The steering capability of thecatheter 12 is illustrated by the bend located at the distal end of thecatheter 12. Steering catheters suitable for use with the present invention are known in the art, and include steering catheters employed in Electrophysiology procedures. Electrophysiology catheters typically provide steering through a combination of rotation and tip bending. - One suitable steerable catheter is described in U.S. Pat. No. 5,656,029, which is incorporated herein by reference. This catheter provides an elongate flexible body that carries a bending mechanism at its distal end. The bending mechanism consists of a shape-memory element typically formed of Nitinol which is provided with a memory which makes it assume a straight condition when it is heated, such as by application of an electrical current. The shape memory element extends through the distal portion of the catheter and is adapted to remain straight along its full length in response to a current passing through the element. To control the location of the bending, an electrical bypass is slidably mounted about the bending element. The bypass element can be an elongate cylindrical sleeve formed of a conductive material and through which the bending element can extend. The bypass element can act as a short circuit that bypasses current away from the bending element. Accordingly, the bypass element prevents current from heating the bending element at the location of the bypass. Consequently, the bending element will bend at the location of the bypass. By allowing the bypass to be slid along the length of the bending element, the physician can select the location of the bypass, thereby selecting the location of bending. As the
delivery chamber 14 is carried at the distal extremity of thecatheter 12, this allows the physician to selectively position thedelivery chamber 14 within the interior of the patient's heart. - The bending elements and bypass elements described above are carried within the
catheter 12 and are not shown in FIG. 1, but however are described in detail in the above identified reference. Additionally, it is noted that although thecatheter 12 has been described with reference to one type of steerable catheter it will be apparent to one of ordinary skill in the art that other suitable steering mechanisms can be employed with the present invention including steering mechanisms that include actuating poles or wires that extend longitudinally through the catheter body. Moreover, it will be further understood that although the depictedcatheter 12 is optionally a steerable catheter, the devices of the invention are not to be limited to steerable devices, and will be understood to encompass conventional catheter systems as well. - Control of the depicted
catheter 12 and thedelivery chamber 14 is provided by the integrated hand-held control mechanism and handle 18 mounted on the proximal end of thecatheter 12. The control mechanism/handle 18 can be of various types, and the depictedhandle 18 is adapted for operating a steerable catheter wherein the bend of the catheter can be selectively controlled by the physician. To these ends, the hand-held control/handle 18 is dimensionally adapted to provide the treating physician with a device that is facile to manipulate and comfortable to hold. Additionally, the hand-held mechanism/handle 18 includes a set of control switches, 16 a, 16 b and 20 that allow the physician to control the steering of thecatheter 12 and the implanting of the depot.Switches catheter 12. Theswitch 16 a can be a slidable switch that allows the physician to control the longitudinal position of the bend within the distal tip of the catheter. Theswitch 16 a can activate the bending mechanism to cause the catheter tip to bend as needed. Thecontrol switch 20 can activate thedelivery chamber 14 to cause a pellet containing a therapeutic agent to be delivered into a tissue wall. - It will be apparent to one of ordinary skill in the art that other control mechanisms/handles can be employed with the systems of the invention without departing from the scope thereof Specifically, other systems can include joystick controls for operating the steerable catheters and can include controls for rotating the angle at which the distal end of the catheter bends. Still other control mechanisms/handles can include pistol grips for providing manual activation of the
delivery chamber 14. Other modifications and additions can be made to the control mechanism/handle without departing from the scope of the invention. - FIG. 2A depicts in greater detail one
delivery chamber 14 which is suitable for being carried at the distal end of thecatheter 12 depicted in FIG. 1. Thedelivery chamber 14 is sized to hold the plurality ofminispheres 22, each of which contains a therapeutic agent. Theminispheres 22 are carried within aninterior chamber 24 which is bound at the proximal end by aplunger 33 and bound at the distal end by a wall formed of a plurality offlexible finger elements 36 that define aport 30. In the embodiment depicted in FIG. 2A, anoptional detent 34 is connected to a sidewall of thechamber 24 to provide a mechanical stop that prevents theminispheres 22 from freely exiting through theport 30. Upon application of mechanical force by theplunger 33, theminispheres 22 can be pushed over thedetent 34, for allowing oneminisphere 22 to be ejected throughport 30. - More specifically, the
plunger 33 depicted in FIG. 2A includes aplate 38 and anactuating rod 40. Theplate 38 is dimensioned to fill substantially the diameter ofinterior chamber 24 to provide thereby a surface that is adapted for forcing theminispheres 22 through thechamber 24 and out ofport 30. The actuatingrod 40 is connected to theplate 38 and provides a mechanical force to plate 38 to advance, or drive, theplate 38 distally into thechamber 24. In one embodiment, the actuatingrod 40 extends through thecatheter 12 and couples to the control mechanism/handle 18 at the proximal end ofdevice 10. In this embodiment, the control mechanism/handle 18 includes a mechanism that drives the actuatingrod 40 distally causingminispheres 22 to be delivered throughport 30. Optionally, this embodiment can include a control mechanism/handle 18 that incorporates a ratchet assembly that drives the actuatingrod 40 distally in discreet steps wherein a predetermined number of steps corresponds substantially to the diameter of one of theminispheres 22. For example, the depictedcontrol switch 20 can be a rotatable switch that allows for manual actuation of a ratchet assembly contained within the control mechanism/handle 18. The ratchet assembly allows the physician to drive theplunger 33 distally into thechamber 24 thereby driving theminisphere 22 out of theport 30. In this way, thedevice 10 can allow for the discreet and sequential delivery ofminispheres 22 from thedelivery chamber 14. - In an alternative embodiment of the invention, the
plunger 33 is threaded to mate with a threaded interior portion ofchamber 24. Manual or motor-driven rotation of actuatingrod 40 will advance or retract the plunger with a finer degree of control than that provided by strictly linear actuation. Such control over the travel distance of theplunger 33 into and out of theinterior chamber 24, gives control over the number ofminispheres 22 delivered throughport 30. - FIG. 2B provides a head-on perspective of the
delivery chamber 14, showing the distal most portion of thedelivery chamber 14 as viewed from a position along the longitudinal axis of thedelivery chamber 14. Together, FIGS. 2A and 2B show that the distal end of thedelivery chamber 14 includes aport 30 that is formed from the convergence of a plurality of flexiblearched fingers 36, each of which is formed from a resilient material and each of which is biased to hold theminispheres 22 within theinterior chamber 24. Upon action of theplunger 33 to move theminispheres 22 distally, thefingers 36 will yield to the axial pressure and release aminisphere 22. Additionally, in the embodiment depicted in FIG. 2A theoptional detent 34 provides further resistance that preventsminispheres 22 from exitingchamber 24 through theport 30 and for providing a tactile sensation that indicates when aminisphere 22 has been released, or has become available to be released, throughport 30. - The
delivery chamber 14 is adapted to facilitate the implantation of a depot of drug within a tissue wall. For example thedelivery chamber 14 can be sized and made of a material rigid enough to facilitate the penetration of the delivery chamber within a tissue wall. Accordingly, the depicteddelivery chamber 14 can be about 0.010 to 0.050 inches in diameter, and about 0.05 to 0.075 inches in length, to have a needle-like profile that is suitable for penetrating tissue. Additionally, the depicteddelivery chamber 14 can be formed of stainless steel or of plastic material that is sufficiently rigid to allow thedelivery chamber 14 to pass into a tissue wall. - FIGS. 3A and 3B depict an alternative embodiment of a delivery chamber suitable for use with the
catheter system 10 shown in FIG. 1. The depicteddelivery chamber 50 includes acylindrical sidewall 58 that defines an interior space that houses aplunger 52. Theplunger 52 includes agrooved plate 62 that can be rotatably driven along thethreads 64 that extend along a portion of thesidewall 58. Accordingly, in this embodiment, theplunger 52 advances into thedelivery chamber 50 as theplate 62 turns across, and travels over thethreads 64. The distal end of theplunger 52 butts against a stack of nesteddrug delivery pellets 60 and forces thepellets 60 against the elongateflexible finger elements 54 that, as shown by FIG. 3B, define theport 56. - The
delivery chamber 50 implants drug pellets having a hollow, conical shape which facilitates the penetration of theimplants 60 into the tissue wall. As shown, theplunger 52 can drive thepellets 60 through theport 56 and into the tissue wall. As discussed above, theflexible fingers 54 are biased to hold thepellets 60 within thechamber 50, however, the mechanical force applied by theplunger 52 will be sufficient to overcome the bias force of thefingers 54. Again as discussed above, a ratchet assembly, a rotary actuator, and/or optionally a detent, can be employed to help the physician control the number of pellets being delivered into the tissue wall. Specifically, the ratchet assembly or rotary actuator controls the distance theplunger 52 is driven into thechamber 50 and the detent provides a tactile sensation each time apellet 60 is moved a predetermined distance. - The
delivery chamber 50 provides an alternative embodiment that allows for the implantation of larger pellets of drugs where the size of the pellet may require a delivery chamber that is too large to readily penetrate through a tissue wall. Accordingly, delivery chambers can be selectively developed for the implantation systems described herein based on the applications of interest and the size of the pellet being delivered. For example, in systems that implant microspheres of drugs having diameters of about 5-15 μm, the delivery chamber can be adapted to hold the microspheres in a fluid medium and a plunger assembly, or other suitable system, can be employed to flush the microspheres from the delivery chamber and into the tissue wall. In this case, the delivery chamber can be simply a hypodermic needle, and a syringe connected to the proximal end of the system can inject the fluid medium through a lumen in thecatheter 12. Other delivery chambers can be employed with the systems described herein without departing from the scope hereof. - The systems described above are capable of implanting pellets that contain a therapeutic agent. The therapeutic agent can be any compound that is biologically active and suitable for long term administration to a tissue or organ. The pellets described above can be formed as mini-spheres that are on the order of about 0.005 inches to about 0.040 inches in diameter. Particles of this size are capable of providing a therapeutically effective dose of agent and can remain where implanted, resisting fluid flux through the tissue wall.
- Techniques and materials for forming pellets capable of acting as drug delivery implants are well known in the art. In one practice, a solid pellet is formed from a biodegradable polymer that has been doped or “seeded” with the desired therapeutic agent. Typically, the polymer is a synthetic polymer, such as poly(lactic acid) or polyorthoesters, and is formed by solvent evaporation, spray drying, or phase separation. Such a
pellet 70 is depicted in FIG. 4A. The polymer is capable of breaking down over time, allowing the drug to be released into the adjacent tissue. To aid in visualizing the implant by fluoroscopy or x-ray, a sphere of a precious metal, such as gold or platinum, can be covered with the drug-filledpolymer 72 in a thickness that provides the desired volume, dosage and/or time release profile. Other acceptable drug delivery implants include the “container” implant which is filled with a liquid drug. A wall of the container is at least partially made of a biodegradable polymer that permits passage of drug molecules at a certain rate. This design is common for injectable microspheres. One advantage is that it can work for drugs that are not amenable to doping in polymers because of heat processes or other incompatibilities. A radioopaque metal core could be incorporated into this “container” type pellet to facilitate viewing. - Additionally, pellets delivered into or against the tissue wall can be coated with or include adhesive materials that adhere to tissue. Further, coatings can be provided that facilitate the absorption of the pellet into the tissue wall. Such coatings can include fumaric acid, sebacic acid and other similar materials.
- FIG. 4B depicts in more detail a
pellet 76 suitable for delivery by thedelivery chamber 50 depicted in FIGS. 3A and 3B. Thepellet 76 is a hollow conical body that provides a pointed end that facilitates delivery of thepellet 76 into a tissue wall. Optionally, thepellet 76 can carry a radio opaque marker (not shown) and, in one embodiment, the radio opaque marker comprises grains of a noble metal which are incorporated into the material of which thepellet 76 is formed. - It will be apparent to one of ordinary skill in the art that other drug delivery implants can be employed with the systems described herein, including disc shaped pills or cylindrical implants that incorporate a solid, drug-filled polymer core with the container-type biodegradable polymer wall. One such implant is described in U.S. Pat. No. 5,629,008, which is incorporated herein in its entirety by reference.
- FIGS. 5 and 6 depict more explicitly one method according to the invention for implanting a therapeutic agent into a tissue wall. The depicted method is a cardiovascular treatment for restenosis that can occur in a coronary artery. The method includes the steps of employing an elongate flexible surgical instrument (e.g., a catheter) having a distal end that carries a
delivery chamber 14. The distal end is inserted into a vascular system of a patient, such as by insertion via a femoral artery or vein. Thedelivery chamber 14 is guided through the patient's vascular system until thedelivery chamber 14 is disposed within the heart, such as within the left ventricle. Once within the heart, the delivery chamber is employed to implant a therapeutic agent into the tissue of the heart. - In a first step the physician can determine the therapeutic agent, or agents, to be implanted and the depot for the selected agents. The depot may be selected by considering, inter alia, the desired time of drug residence within the tissue and the desired dosage to be eluted during the course of the residence. Optionally, the pellets can carry a plurality of therapeutic agents, either by solidifying a plurality of agents within the polymer coating of each pellet, or by providing pellets carrying different therapeutic agents. This latter practice allows the physician to load both active therapeutic agents and agents capable of activating therapeutic agents upon contact, or capable of degrading the polymer wall of an implanted pellet. This can allow for greater time delay before activation of an agent, and for greater selection in the delivery vehicle and the agents and drugs being delivered. Once the agents are selected, the physician can select the delivery chamber to use and can pre-load the delivery chamber with a plurality of pellets, each of which can be a minisphere, a helical, conical pellet, a cylindrical container, or other device capable of being implanted into the myocardium. The physician can preload the
delivery chamber 14 with the set of pellets that have been selected to deliver the proper depot of therapeutic agent to the tissue around an artery that is suffering from, or may suffer from, restentosis. Alternatively, pellets containing a desired therapeutic agent can be preloaded into the delivery system, which is provided to the physician as a sterile, disposable item. - Before delivering the preloaded
delivery chamber 14 into the heart, the treating physician optionally performs a preliminary step of positioning a radio-opaque marker at the site of restenosis. This allows the treating physician to view the marker during delivery of the pellets. The marker can be a stent, or any viewable marker that will remain present at the site of the localized disease during the implanting of the drug delivery pellets. - In one practice, the marker can be the radio-opaque marker of a balloon being employed during a PTCA procedure. Specifically, as restenosis may arise from the site of the angioplasty, one practice of the invention performs the drug delivery at the same time as the angioplasty. In this procedure, the treating physician leaves the PTCA catheter in place, while the delivery implant system is guided to the target area. A radiopaque marker in the balloon gives fluoroscopic guidance during the implant procedure.
- At this time, the physician can guide the implant system along the appropriate delivery route until the catheter enters the interior of the patient's heart. The delivery chamber can approach target areas from within any chamber of the heart. Notably, the practices described herein allow that even septal arteries can be treated for cardiac conditions or to stimulate angiogenisis. In FIG. 5, the delivery chamber is shown as approaching the target area from the interior of the heart, and positioning the delivery chamber against the endocardial tissue over the myocardium. Upon positioning the delivery chamber adjacent the interior tissue wall of the heart, the physician drives the delivery chamber into the tissue and to the targeted area. The physician actuates the control mechanism and ejects a pellet from the delivery chamber, implanting the pellet within the targeted area of the myocardium.
- It is a realization of the present invention that the practices described herein are often suitable for arteries normally considered epicardial, with little surrounding myocardial tissue or subepicardial fat in which to implant the drug delivery pellets. Specifically, researchers have noted that tunneled epicardial coronary arteries may represent a normal variant being recognized in up to 86% of vessels. Waller,Anatomy, Histology, and Pathology of the Major Epicardial Coronary Arteries Relevant to Echocardiographic Imaging Techniques, Journal of American Society of Echocardiographic Imaging, vol. 2 (1989).
- FIG. 6 illustrates a further realization of the present invention. FIG. 6 shows that it is desirable to implant the pellets as close as possible to the artery being treated, and that providing an array of implanted pellets about the periphery of the artery may provide sufficient localized elution of therapeutic agent to prevent restenosis. In one practice, the pellets are implanted through a single point of entry through the myocardium. The physician manipulates the distal tip of the catheter to dispose the port of the delivery chamber at the depicted locations. At each location, a pellet is ejected from the delivery chamber and implanted into the myocardium.
- FIG. 7 depicts a further alternative embodiment of the invention. The depicted
system 80 includes ashort catheter 82 that carries adelivery chamber 84 at its distal end and that connects at its proximal end to a pistolgrip control mechanism 88. - The
system 80 is adapted for use during an endoscopic procedure and to that end the depictedcatheter 84 is a short catheter adapted to slide within a endoscopic port that has been placed through the chest and positioned abutting the pericardium. Thedelivery chamber 84 can be a delivery chamber as discussed above and can be dimensionally adapted to penetrate and extend through the pericardial sac. The delivery chamber can penetrate into the myocardium and thereby allow the physician to implant pellets into the myocardium. Optionally, thecatheter 82 can be a steerable catheter which allows the physician to bend the distal tip of thecatheter 82 to place thedelivery chamber 84 where needed. Alternatively, the catheter can include a deflectable tip, as is known in the art, which the physician can direct to the targeted area. Other modifications to thesystem 80, including providing the catheter with a fiber optic viewing device to allow the physician to view the interior of the pericardial sac, can be made without departing from the scope of the invention. - The depicted
pistol grip 88 provides the physician with a manual actuator that allows the physician to control the implanting of pellets within the myocardium. Thepistol grip 88 can be a molded plastic assembly of the type well known in the art for actuating a mechanical assembly, such as the plunger assembly of thedelivery chamber 14 described above. - In a further practice, the techniques of the invention can be employed during an open chest procedure. Specifically, the surgeon performing the open chest operation can employ a delivery device that includes a delivery chamber as described above to implant pellets into the myocardium. Additionally, in this practice, the physician can employ a hypodermic needle to inject a solution containing microspheres of a therapeutic agent. Other practices of the invention can be practiced without departing from the scope thereof.
- Moreover, the systems and methods for implanting depots of therapeutic agents can be applied to conditions other than those relating to cardiac failure. For example, the systems described herein can be applied to the treatment of muscle tissue afflicted by insufficient circulation. In one practice, the systems described herein are employed to deliver a human angiogenic growth factor, such as VGEF, which is understood to stimulate the growth of blood vessels. Thus, the systems described herein can promote the survival of muscle tissue that is moribund as a result of poor circulation due to failing or occluding blood vessels.
- Those skilled in the art will know or be able to ascertain using no more than routine experimentation, many equivalents to the embodiments and practices described herein. For example, the devices described herein can be used in cooperation with drilling elements or laser devices capable of forming an opening in a tissue wall, such as the myocardium. The delivery chamber can be inserted into the preformed openings for delivering a therapeutic agent therein. Further, pellets according to the invention can include threaded exterior surfaces that facilitate implanting the pellet within a tissue wall. Accordingly, it will be understood that the invention is not to be limited to the embodiments disclosed herein, but is to be understood from the following claims, which are to be interpreted as broadly as allowed under the law.
Claims (31)
1. A method for providing local delivery of a therapeutic agent, comprising the step of implanting said therapeutic agent into a portion of myocardial tissue.
2. A method according to , including the steps of
claim 1
providing a catheter having a distal end adapted for delivering said therapeutic agent,
guiding said catheter into the interior of a patient's heart, and
disposing said distal end against an endocardial wall of the heart for implanting said therapeutic agent into the myocardial tissue.
3. A method according to including the further step of,
claim 1
providing a steerable catheter having a drilling element for penetrating an endocardial wall.
4. A method according to , including the step of
claim 1
delivering a pellet containing said therapeutic agent into the myocardial tissue.
5. A method according to , including the step of
claim 4
delivering sequentially a plurality of pellets containing said therapeutic agent into the myocardial tissue.
6. A method according to , including the step of
claim 1
providing a pellet containing said therapeutic agent and a radio-opaque material.
7. A method according to , including the step of
claim 2
steering said catheter through the femoral artery and into the heart.
8. A method according to , including the step of
claim 2
positioning a marker in a selected portion of a coronary artery, for providing a marker to identify a location for receiving said therapeutic agent.
9. A method according to , including the step of
claim 2
penetrating said distal end of said catheter through said endocardial wall, for delivering said therapeutic agent into said myocardial tissue.
10. A method according to , including the step of
claim 2
delivering through said distal end of said catheter, a pellet having a pointed or helical, conical end adapted to penetrate said endocardial wall.
11. A method according to , including the step of
claim 2
delivering pellets containing said therapeutic agent and having an outer surface adapted to adhere said pellets to said endocardial wall.
12. A method according to , including the step of
claim 1
endoscopically delivering said therapeutic agent through the epicardium.
13. A method according to , including the step of
claim 1
implanting said therapeutic agent into the myocardial tissue during open-chest surgery.
14. A method for delivering a pellet containing a therapeutic agent, comprising the steps of
providing a catheter having a distal end adapted for delivering said pellet,
guiding said catheter through a body lumen and disposing said distal end proximate a tissue wall, and
delivering said pellet through said distal end with sufficient force to implant said pellet within said tissue wall.
15. A method for delivering a therapeutic agent to a septal artery, comprising the steps of
providing a catheter having a distal end adapted for delivering said therapeutic agent,
guiding said catheter into the interior of a patient's heart, and
disposing said distal end against a septal wall of the heart for implanting said therapeutic agent into the septal wall.
16. A method according to , wherein the step of disposing said distal end of the catheter includes a step of,
claim 15
delivering a pellet containing said therapeutic agent from said distal end with sufficient force to implant said pellet within the septal wall.
17. A method according to , wherein the step of disposing said distal end of the catheter includes a step of,
claim 15
delivering from said distal end of the catheter a pellet containing said therapeutic agent and having a surface adapted to adhere to a tissue wall.
18. A method for treating vascular restenosis, comprising the steps of
identifying a portion of tissue proximate to a site of a patient's vasculature to be treated for restenosis, and
implanting a therapeutic agent into the portion of tissue.
19. A pellet, comprising
a therapeutic agent surrounding a radio-opaque material, whereby delivery of the therapeutic agent is facilitated by viewing the position of the radio-opaque material relative to a position of a targeted site for implanting the pellet.
20. Apparatus for implanting a therapeutic agent within a tissue wall, comprising
an elongate flexible body having a proximal end and a distal end,
a delivery chamber coupled to the distal end of the body and having a space for carrying the therapeutic agent, and a port for releasing the therapeutic agent therefrom, and
an actuator coupled to the delivery chamber and capable of driving the therapeutic agent through the port, whereby the therapeutic agent is implanted within a tissue wall.
21. Apparatus according to , further including
claim 20
a control mechanism coupled to the actuator and the proximal end of the body for providing control of the actuator, whereby a user can operate the control mechanism for controlling the delivery of the therapeutic agent.
22. Apparatus according to , further including
claim 20
a steering mechanism for turning the distal end of the body, to thereby allow the delivery chamber to be selectively guided through a body lumen.
23. Apparatus according to , wherein the delivery chamber and the distal end of the flexible body are dimensionally adapted to allow for transluminal delivery and for entry into the interior of a patient's heart.
claim 20
24. Apparatus according to , wherein the delivery chamber includes a substantially cylindrical interior housing dimensionally adapted to store in axial alignment a plurality of minispheres containing a therapeutic agent.
claim 20
25. Apparatus according to , further including
claim 20
a pointed distal end adapted to penetrate a tissue wall for delivering the therapeutic agent within the tissue wall.
26. Apparatus according to , wherein the actuator includes
claim 20
a plunger for driving the therapeutic agent from the delivery chamber.
27. Apparatus according to , further including
claim 20
a ratchet assembly for allowing delivery of discreet volumes of the therapeutic agent.
28. Apparatus according to , wherein the actuator includes
claim 20
a threaded plunger for advancing into the delivery chamber responsive to a rotating action.
29. Apparatus according to , wherein the delivery chamber is adapted to receive at least one pellet containing the therapeutic agent.
claim 20
30. Apparatus according to , further including
claim 20
a lever-action handle mounted at the proximal end of the flexible body and coupled to the control mechanism.
31. Apparatus according to , further including
claim 20
means for receiving at least one pellet containing the therapeutic agent and having an arcuate shape for facilitating implanting within a body of tissue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/888,757 US20010033867A1 (en) | 1997-12-18 | 2001-06-25 | Systems and methods for local delivery of an agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/993,586 US6251418B1 (en) | 1997-12-18 | 1997-12-18 | Systems and methods for local delivery of an agent |
US09/888,757 US20010033867A1 (en) | 1997-12-18 | 2001-06-25 | Systems and methods for local delivery of an agent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/993,586 Division US6251418B1 (en) | 1997-12-18 | 1997-12-18 | Systems and methods for local delivery of an agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010033867A1 true US20010033867A1 (en) | 2001-10-25 |
Family
ID=25539727
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/993,586 Expired - Fee Related US6251418B1 (en) | 1997-12-18 | 1997-12-18 | Systems and methods for local delivery of an agent |
US09/888,757 Abandoned US20010033867A1 (en) | 1997-12-18 | 2001-06-25 | Systems and methods for local delivery of an agent |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/993,586 Expired - Fee Related US6251418B1 (en) | 1997-12-18 | 1997-12-18 | Systems and methods for local delivery of an agent |
Country Status (6)
Country | Link |
---|---|
US (2) | US6251418B1 (en) |
EP (1) | EP1047471B1 (en) |
JP (1) | JP2002508227A (en) |
DE (1) | DE69831978T2 (en) |
ES (1) | ES2251123T3 (en) |
WO (1) | WO1999030764A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105940A2 (en) | 2002-06-17 | 2003-12-24 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US20040236213A1 (en) * | 2003-05-23 | 2004-11-25 | Senorx, Inc. | Marker delivery device with releasable plug |
US20050119562A1 (en) * | 2003-05-23 | 2005-06-02 | Senorx, Inc. | Fibrous marker formed of synthetic polymer strands |
US20050143656A1 (en) * | 1999-02-02 | 2005-06-30 | Senorx, Inc. | Cavity-filling biopsy site markers |
US20060084865A1 (en) * | 1999-02-02 | 2006-04-20 | Burbank Fred H | Imageable biopsy site marker |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
US20090287078A1 (en) * | 2003-05-23 | 2009-11-19 | Senorx, Inc. | Marker or filler forming fluid |
WO2012126000A2 (en) * | 2011-03-17 | 2012-09-20 | Emory University | Delivery devices and methods for delivering therapeutic agents |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US20140180065A1 (en) * | 2011-05-11 | 2014-06-26 | The Regents Of The University Of California | Fiduciary markers and methods of placement |
US9149341B2 (en) | 1999-02-02 | 2015-10-06 | Senorx, Inc | Deployment of polysaccharide markers for treating a site within a patient |
US9295393B2 (en) | 2012-11-09 | 2016-03-29 | Elwha Llc | Embolism deflector |
US20160279200A1 (en) * | 2001-04-27 | 2016-09-29 | Cormend Technologies, Llc | Prevention of myocardial infarction induced ventricular expansion and remodeling |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US10384048B2 (en) | 2014-07-25 | 2019-08-20 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having an occluding member |
US10549081B2 (en) | 2016-06-23 | 2020-02-04 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US11478587B2 (en) | 2016-11-08 | 2022-10-25 | Warsaw Orthopedic, Inc. | Drug depot delivery system and method |
US11759614B2 (en) | 2015-11-23 | 2023-09-19 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6723082B1 (en) * | 1995-05-10 | 2004-04-20 | Sam G. Payne | Delivery catheter system for heart chamber |
US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US7637948B2 (en) | 1997-10-10 | 2009-12-29 | Senorx, Inc. | Tissue marking implant |
US7713190B2 (en) * | 1998-02-24 | 2010-05-11 | Hansen Medical, Inc. | Flexible instrument |
US6347241B2 (en) * | 1999-02-02 | 2002-02-12 | Senorx, Inc. | Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it |
US6406488B1 (en) * | 1998-08-27 | 2002-06-18 | Heartstent Corporation | Healing transmyocardial implant |
US6254564B1 (en) | 1998-09-10 | 2001-07-03 | Percardia, Inc. | Left ventricular conduit with blood vessel graft |
US6261304B1 (en) | 1998-09-10 | 2001-07-17 | Percardia, Inc. | Delivery methods for left ventricular conduit |
EP1112041A1 (en) * | 1998-09-10 | 2001-07-04 | Percardia, Inc. | Tmr shunt |
US6290728B1 (en) * | 1998-09-10 | 2001-09-18 | Percardia, Inc. | Designs for left ventricular conduit |
US6689121B1 (en) * | 1998-09-24 | 2004-02-10 | C. R. Bard, Inc. | Systems and methods for treating ischemia |
US6432126B1 (en) * | 1998-09-30 | 2002-08-13 | C.R. Bard, Inc. | Flexible vascular inducing implants |
US6458092B1 (en) | 1998-09-30 | 2002-10-01 | C. R. Bard, Inc. | Vascular inducing implants |
US6102932A (en) * | 1998-12-15 | 2000-08-15 | Micrus Corporation | Intravascular device push wire delivery system |
US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US6620170B1 (en) | 1999-04-26 | 2003-09-16 | C. R. Bard, Inc. | Devices and methods for treating ischemia by creating a fibrin plug |
US6719805B1 (en) * | 1999-06-09 | 2004-04-13 | C. R. Bard, Inc. | Devices and methods for treating tissue |
US6575991B1 (en) | 1999-06-17 | 2003-06-10 | Inrad, Inc. | Apparatus for the percutaneous marking of a lesion |
US6632184B1 (en) * | 2000-02-11 | 2003-10-14 | Regents Of The University Of Minnesota | Method and device for deflecting a probe |
WO2001064907A2 (en) * | 2000-03-02 | 2001-09-07 | Incyte Genomics, Inc. | Lipid metabolism enzymes |
US6450938B1 (en) * | 2000-03-21 | 2002-09-17 | Promex, Llc | Brachytherapy device |
JP3782297B2 (en) * | 2000-03-28 | 2006-06-07 | 株式会社東芝 | Solid-state imaging device and manufacturing method thereof |
US6854467B2 (en) * | 2000-05-04 | 2005-02-15 | Percardia, Inc. | Methods and devices for delivering a ventricular stent |
US20020032478A1 (en) * | 2000-08-07 | 2002-03-14 | Percardia, Inc. | Myocardial stents and related methods of providing direct blood flow from a heart chamber to a coronary vessel |
CA2659518A1 (en) | 2000-11-20 | 2002-05-30 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US20020077687A1 (en) * | 2000-12-14 | 2002-06-20 | Ahn Samuel S. | Catheter assembly for treating ischemic tissue |
EP1379197A4 (en) * | 2001-03-23 | 2009-06-03 | Durect Corp | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
CA2457142A1 (en) | 2001-08-17 | 2003-02-27 | University Of Pittsburgh | Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
US6943267B1 (en) | 2001-08-24 | 2005-09-13 | Utah State University | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases |
US20080279936A1 (en) * | 2001-10-10 | 2008-11-13 | The University Of Pittsburgh | Estradiol metabolites for reduction of endothelin production |
SG148850A1 (en) * | 2002-02-13 | 2009-01-29 | Beth Israel Hospital | Methods of treating vascular disease |
WO2003088748A1 (en) | 2002-04-15 | 2003-10-30 | Beth Israel Deaconess Medical Center | Use of heme oxygenase-1 and products of heme degradation |
US20030229332A1 (en) * | 2002-06-11 | 2003-12-11 | Scimed Life Systems, Inc. | Adjustable double balloon catheter with a through lumen for stone management |
US20040131703A1 (en) * | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
US7347829B2 (en) * | 2002-10-07 | 2008-03-25 | Suros Surgical Systems, Inc. | Introduction system for minimally invasive surgical instruments |
US20080161720A1 (en) * | 2002-10-07 | 2008-07-03 | Nicoson Zachary R | Registration system |
US20070260267A1 (en) * | 2002-10-07 | 2007-11-08 | Nicoson Zachary R | Localizing obturator |
JP3960904B2 (en) * | 2002-11-08 | 2007-08-15 | オリンパスメディカルシステムズ株式会社 | Transendoscopic medical device |
US20060036158A1 (en) | 2003-11-17 | 2006-02-16 | Inrad, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US6928669B2 (en) * | 2003-01-10 | 2005-08-16 | Tyler Pipe Company | Closet carrier system and method of assembly |
US20060194775A1 (en) * | 2003-02-20 | 2006-08-31 | University Of Pittsburgh | Estradiol metabolites for the treatment of pulmonary hypertension |
EP1610798A4 (en) * | 2003-02-20 | 2007-08-08 | Univ Pittsburgh | Estradiol metabolites for the treatment of pulmonary hypertension |
US8246974B2 (en) | 2003-05-02 | 2012-08-21 | Surmodics, Inc. | Medical devices and methods for producing the same |
ATE476960T1 (en) * | 2003-05-02 | 2010-08-15 | Surmodics Inc | SYSTEM FOR THE CONTROLLED RELEASE OF A BIOACTIVE INGREDIENT IN THE BACK OF THE EYE |
US8048003B2 (en) | 2003-10-14 | 2011-11-01 | Suros Surgical Systems, Inc. | Vacuum assisted biopsy device |
US7988642B2 (en) | 2003-10-14 | 2011-08-02 | Suros Surgical Systems, Inc. | Vacuum assisted biopsy device |
US8357103B2 (en) * | 2003-10-14 | 2013-01-22 | Suros Surgical Systems, Inc. | Vacuum assisted biopsy needle set |
EP1673015B1 (en) | 2003-10-14 | 2014-03-19 | Suros Surgical Systems, Inc. | Vacuum assisted biopsy needle set |
US20050273002A1 (en) | 2004-06-04 | 2005-12-08 | Goosen Ryan L | Multi-mode imaging marker |
US9408592B2 (en) | 2003-12-23 | 2016-08-09 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
US8932233B2 (en) | 2004-05-21 | 2015-01-13 | Devicor Medical Products, Inc. | MRI biopsy device |
US9638770B2 (en) | 2004-05-21 | 2017-05-02 | Devicor Medical Products, Inc. | MRI biopsy apparatus incorporating an imageable penetrating portion |
US7708751B2 (en) | 2004-05-21 | 2010-05-04 | Ethicon Endo-Surgery, Inc. | MRI biopsy device |
US20060024350A1 (en) * | 2004-06-24 | 2006-02-02 | Varner Signe E | Biodegradable ocular devices, methods and systems |
WO2006023130A2 (en) * | 2004-08-12 | 2006-03-02 | Surmodics, Inc. | Biodegradable controlled release bioactive agent delivery device |
US8360990B2 (en) | 2004-12-16 | 2013-01-29 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
DE102005003632A1 (en) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Catheter for the transvascular implantation of heart valve prostheses |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
US9095325B2 (en) | 2005-05-23 | 2015-08-04 | Senorx, Inc. | Tissue cutting member for a biopsy device |
US7572236B2 (en) | 2005-08-05 | 2009-08-11 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US8317725B2 (en) | 2005-08-05 | 2012-11-27 | Senorx, Inc. | Biopsy device with fluid delivery to tissue specimens |
US8052658B2 (en) | 2005-10-07 | 2011-11-08 | Bard Peripheral Vascular, Inc. | Drug-eluting tissue marker |
JP2009517343A (en) | 2005-11-14 | 2009-04-30 | エンタープライズ パートナーズ ベンチャー キャピタル | Stem cell factor therapy for tissue damage |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US20070184083A1 (en) * | 2006-02-07 | 2007-08-09 | Medtronic Vascular, Inc. | Drug-Eluting Device for Treatment of Chronic Total Occlusions |
US20080230001A1 (en) * | 2006-02-23 | 2008-09-25 | Meadwestvaco Corporation | Method for treating a substrate |
US20070293873A1 (en) * | 2006-06-19 | 2007-12-20 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
US8668676B2 (en) * | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
US9039761B2 (en) | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
US8064987B2 (en) | 2006-10-23 | 2011-11-22 | C. R. Bard, Inc. | Breast marker |
EP3542748B1 (en) | 2006-12-12 | 2023-08-16 | C. R. Bard, Inc. | Multiple imaging mode tissue marker |
ES2432572T3 (en) | 2006-12-18 | 2013-12-04 | C.R. Bard, Inc. | Biopsy marker with imaging properties generated in situ |
US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
US8808200B2 (en) | 2007-10-01 | 2014-08-19 | Suros Surgical Systems, Inc. | Surgical device and method of using same |
US8202229B2 (en) | 2007-10-01 | 2012-06-19 | Suros Surgical Systems, Inc. | Surgical device |
US8311610B2 (en) | 2008-01-31 | 2012-11-13 | C. R. Bard, Inc. | Biopsy tissue marker |
US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
WO2011104269A1 (en) | 2008-02-26 | 2011-09-01 | Jenavalve Technology Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US20090247900A1 (en) * | 2008-03-25 | 2009-10-01 | Brian Zimmer | Push button adjustable spacer |
US20090247901A1 (en) * | 2008-03-25 | 2009-10-01 | Brian Zimmer | Latching side removal spacer |
US8016799B2 (en) * | 2008-04-22 | 2011-09-13 | Medtronic Vascular, Inc. | Catheter having a detachable tip |
US8043316B2 (en) * | 2008-05-02 | 2011-10-25 | Suros Surgical Systems, Inc. | Adjustable spacer |
US9327061B2 (en) | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
US8670818B2 (en) | 2008-12-30 | 2014-03-11 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US8545554B2 (en) * | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
US20110275891A1 (en) * | 2009-01-27 | 2011-11-10 | Silenseed Ltd. | Method and system for implant delivery |
US20100292641A1 (en) * | 2009-05-15 | 2010-11-18 | Bandula Wijay | Targeted drug delivery device and method |
JP2013526388A (en) | 2010-05-25 | 2013-06-24 | イエナバルブ テクノロジー インク | Artificial heart valve, and transcatheter delivery prosthesis comprising an artificial heart valve and a stent |
US9162036B2 (en) | 2011-12-30 | 2015-10-20 | Biosense Webster (Israel), Ltd. | Medical device control handle with multiple puller wires |
JP6549482B2 (en) | 2012-06-01 | 2019-07-24 | サーモディクス,インコーポレイテッド | Device and method for coating a balloon catheter |
US9827401B2 (en) | 2012-06-01 | 2017-11-28 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US11090468B2 (en) | 2012-10-25 | 2021-08-17 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
CN105491978A (en) | 2013-08-30 | 2016-04-13 | 耶拿阀门科技股份有限公司 | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
USD715442S1 (en) | 2013-09-24 | 2014-10-14 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715942S1 (en) | 2013-09-24 | 2014-10-21 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716450S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716451S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
US10743960B2 (en) | 2014-09-04 | 2020-08-18 | AtaCor Medical, Inc. | Cardiac arrhythmia treatment devices and delivery |
US10328268B2 (en) | 2014-09-04 | 2019-06-25 | AtaCor Medical, Inc. | Cardiac pacing |
US11097109B2 (en) | 2014-11-24 | 2021-08-24 | AtaCor Medical, Inc. | Cardiac pacing sensing and control |
SG11201704797TA (en) | 2014-12-23 | 2017-07-28 | Acelrx Pharmaceuticals Inc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
DE102015103748A1 (en) | 2015-03-13 | 2016-09-15 | Henke-Sass, Wolf Gmbh | Magazine for holding pellets for use in an injector |
US10709555B2 (en) | 2015-05-01 | 2020-07-14 | Jenavalve Technology, Inc. | Device and method with reduced pacemaker rate in heart valve replacement |
US20170038184A1 (en) * | 2015-08-06 | 2017-02-09 | Charles E. Ankner | Formulation delivery system |
EP3454795B1 (en) | 2016-05-13 | 2023-01-11 | JenaValve Technology, Inc. | Heart valve prosthesis delivery system for delivery of heart valve prosthesis with introducer sheath and loading system |
CN110392557A (en) | 2017-01-27 | 2019-10-29 | 耶拿阀门科技股份有限公司 | Heart valve simulation |
US11628466B2 (en) | 2018-11-29 | 2023-04-18 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US11819590B2 (en) | 2019-05-13 | 2023-11-21 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
WO2020243534A1 (en) | 2019-05-29 | 2020-12-03 | AtaCor Medical, Inc. | Implantable electrical leads and associated delivery systems |
US11471650B2 (en) | 2019-09-20 | 2022-10-18 | Biosense Webster (Israel) Ltd. | Mechanism for manipulating a puller wire |
US11666771B2 (en) | 2020-05-29 | 2023-06-06 | AtaCor Medical, Inc. | Implantable electrical leads and associated delivery systems |
Citations (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2269963A (en) * | 1940-06-01 | 1942-01-13 | Wappler Frederick Charles | Implanting device |
US2969963A (en) * | 1958-05-07 | 1961-01-31 | Brown Engine Products Inc | Carburetor |
US3680544A (en) * | 1970-09-09 | 1972-08-01 | James P Shinnick | Transthoracic cannula-type device for cardiopulmonary resuscitation |
US4451253A (en) * | 1980-12-18 | 1984-05-29 | Harman Sherman M | Means and method for administering medicinals |
US4457712A (en) * | 1979-11-13 | 1984-07-03 | Dragan William B | Dental syringe |
US4461280A (en) * | 1980-12-15 | 1984-07-24 | Baumgartner George C | Surgical instrument and process |
US4503569A (en) * | 1983-03-03 | 1985-03-12 | Dotter Charles T | Transluminally placed expandable graft prosthesis |
US4562597A (en) * | 1982-12-13 | 1986-01-07 | Possis Medical, Inc. | Method of supplying blood to blood receiving vessels |
US4579061A (en) * | 1984-06-29 | 1986-04-01 | Rexnord Inc. | Spike driving machine including improved rail clamping apparatus |
US4580568A (en) * | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
US4582181A (en) * | 1983-08-12 | 1986-04-15 | Advanced Cardiovascular Systems, Inc. | Steerable dilatation catheter |
US4588395A (en) * | 1978-03-10 | 1986-05-13 | Lemelson Jerome H | Catheter and method |
US4641653A (en) * | 1978-06-02 | 1987-02-10 | Rockey Arthur G | Medical sleeve |
US4649922A (en) * | 1986-01-23 | 1987-03-17 | Wiktor Donimik M | Catheter arrangement having a variable diameter tip and spring prosthesis |
US4655771A (en) * | 1982-04-30 | 1987-04-07 | Shepherd Patents S.A. | Prosthesis comprising an expansible or contractile tubular body |
US4658817A (en) * | 1985-04-01 | 1987-04-21 | Children's Hospital Medical Center | Method and apparatus for transmyocardial revascularization using a laser |
US4665918A (en) * | 1986-01-06 | 1987-05-19 | Garza Gilbert A | Prosthesis system and method |
US4681110A (en) * | 1985-12-02 | 1987-07-21 | Wiktor Dominik M | Catheter arrangement having a blood vessel liner, and method of using it |
US4700692A (en) * | 1985-12-23 | 1987-10-20 | Baumgartner George C | Surgical implantation method and apparatus |
US4718425A (en) * | 1985-05-29 | 1988-01-12 | Mitsui Toatsu Chemicals Incorporated | Catheter with pressure sensor |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4768507A (en) * | 1986-02-24 | 1988-09-06 | Medinnovations, Inc. | Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis |
US4774949A (en) * | 1983-06-14 | 1988-10-04 | Fogarty Thomas J | Deflector guiding catheter |
US4813925A (en) * | 1987-04-21 | 1989-03-21 | Medical Engineering Corporation | Spiral ureteral stent |
US4852580A (en) * | 1986-09-17 | 1989-08-01 | Axiom Medical, Inc. | Catheter for measuring bioimpedance |
US4861336A (en) * | 1987-04-01 | 1989-08-29 | Helzel Manfred W | Puncture catheter |
US4861330A (en) * | 1987-03-12 | 1989-08-29 | Gene Voss | Cardiac assist device and method |
US4909250A (en) * | 1988-11-14 | 1990-03-20 | Smith Joseph R | Implant system for animal identification |
US4917666A (en) * | 1988-11-14 | 1990-04-17 | Medtronic Versaflex, Inc. | Steerable thru-lumen catheter |
US4920980A (en) * | 1987-09-14 | 1990-05-01 | Cordis Corporation | Catheter with controllable tip |
US4950227A (en) * | 1988-11-07 | 1990-08-21 | Boston Scientific Corporation | Stent delivery system |
US4995857A (en) * | 1989-04-07 | 1991-02-26 | Arnold John R | Left ventricular assist device and method for temporary and permanent procedures |
US4997431A (en) * | 1989-08-30 | 1991-03-05 | Angeion Corporation | Catheter |
US5040543A (en) * | 1990-07-25 | 1991-08-20 | C. R. Bard, Inc. | Movable core guidewire |
US5042486A (en) * | 1989-09-29 | 1991-08-27 | Siemens Aktiengesellschaft | Catheter locatable with non-ionizing field and method for locating same |
US5047028A (en) * | 1989-05-12 | 1991-09-10 | Quinghua Qian | Method for inducing thrombosis in blood vessels |
US5049138A (en) * | 1989-11-13 | 1991-09-17 | Boston Scientific Corporation | Catheter with dissolvable tip |
US5056517A (en) * | 1989-07-24 | 1991-10-15 | Consiglio Nazionale Delle Ricerche | Biomagnetically localizable multipurpose catheter and method for magnetocardiographic guided intracardiac mapping, biopsy and ablation of cardiac arrhythmias |
US5087243A (en) * | 1990-06-18 | 1992-02-11 | Boaz Avitall | Myocardial iontophoresis |
US5098374A (en) * | 1987-09-02 | 1992-03-24 | Engineers & Doctors A/A | Device for the placing of a partial catheter in a body cavity |
US5114414A (en) * | 1984-09-18 | 1992-05-19 | Medtronic, Inc. | Low profile steerable catheter |
US5176626A (en) * | 1992-01-15 | 1993-01-05 | Wilson-Cook Medical, Inc. | Indwelling stent |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5190058A (en) * | 1991-05-22 | 1993-03-02 | Medtronic, Inc. | Method of using a temporary stent catheter |
US5287861A (en) * | 1992-10-30 | 1994-02-22 | Wilk Peter J | Coronary artery by-pass method and associated catheter |
US5290295A (en) * | 1992-07-15 | 1994-03-01 | Querals & Fine, Inc. | Insertion tool for an intraluminal graft procedure |
US5312456A (en) * | 1991-01-31 | 1994-05-17 | Carnegie Mellon University | Micromechanical barb and method for making the same |
US5322510A (en) * | 1989-11-21 | 1994-06-21 | Andreas Lindner | Injection apparatus |
US5324325A (en) * | 1991-06-27 | 1994-06-28 | Siemens Pacesetter, Inc. | Myocardial steroid releasing lead |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5342394A (en) * | 1990-05-16 | 1994-08-30 | Olympus Optical Co., Ltd. | Apparatus for blocking a vein branch and method of blocking a vein branch |
US5380316A (en) * | 1990-12-18 | 1995-01-10 | Advanced Cardiovascular Systems, Inc. | Method for intra-operative myocardial device revascularization |
US5386828A (en) * | 1991-12-23 | 1995-02-07 | Sims Deltec, Inc. | Guide wire apparatus with location sensing member |
US5389096A (en) * | 1990-12-18 | 1995-02-14 | Advanced Cardiovascular Systems | System and method for percutaneous myocardial revascularization |
US5391199A (en) * | 1993-07-20 | 1995-02-21 | Biosense, Inc. | Apparatus and method for treating cardiac arrhythmias |
US5405376A (en) * | 1993-08-27 | 1995-04-11 | Medtronic, Inc. | Method and apparatus for ablation |
US5409004A (en) * | 1993-06-11 | 1995-04-25 | Cook Incorporated | Localization device with radiopaque markings |
US5409019A (en) * | 1992-10-30 | 1995-04-25 | Wilk; Peter J. | Coronary artery by-pass method |
USRE34936E (en) * | 1986-10-06 | 1995-05-09 | Bio Medic Data Systems, Inc. | Animal marker implanting system |
US5423885A (en) * | 1992-01-31 | 1995-06-13 | Advanced Cardiovascular Systems, Inc. | Stent capable of attachment within a body lumen |
US5425757A (en) * | 1993-05-21 | 1995-06-20 | Tiefenbrun; Jonathan | Aortic surgical procedure |
US5429144A (en) * | 1992-10-30 | 1995-07-04 | Wilk; Peter J. | Coronary artery by-pass method |
US5441516A (en) * | 1994-03-03 | 1995-08-15 | Scimed Lifesystems Inc. | Temporary stent |
US5446499A (en) * | 1992-12-23 | 1995-08-29 | Daewoo Electronics Co., Inc. | Window signal generating apparatus |
US5452733A (en) * | 1993-02-22 | 1995-09-26 | Stanford Surgical Technologies, Inc. | Methods for performing thoracoscopic coronary artery bypass |
US5453090A (en) * | 1994-03-01 | 1995-09-26 | Cordis Corporation | Method of stent delivery through an elongate softenable sheath |
US5487739A (en) * | 1987-11-17 | 1996-01-30 | Brown University Research Foundation | Implantable therapy systems and methods |
US5501664A (en) * | 1991-07-02 | 1996-03-26 | Intermed, Inc. | Subcutaneous drug delivery device |
US5514176A (en) * | 1995-01-20 | 1996-05-07 | Vance Products Inc. | Pull apart coil stent |
US5551954A (en) * | 1991-10-04 | 1996-09-03 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5558091A (en) * | 1993-10-06 | 1996-09-24 | Biosense, Inc. | Magnetic determination of position and orientation |
US5602301A (en) * | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
US5618563A (en) * | 1992-09-10 | 1997-04-08 | Children's Medical Center Corporation | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
US5629008A (en) * | 1992-06-02 | 1997-05-13 | C.R. Bard, Inc. | Method and device for long-term delivery of drugs |
US5635215A (en) * | 1991-05-29 | 1997-06-03 | Biosepra S.A. | Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same |
US5643308A (en) * | 1995-02-28 | 1997-07-01 | Markman; Barry Stephen | Method and apparatus for forming multiple cavities for placement of hair grafts |
US5656029A (en) * | 1992-12-01 | 1997-08-12 | Cardiac Pathways Corporation | Steerable catheter with adjustable bend location and/or radius and method |
US5655548A (en) * | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
US5662124A (en) * | 1996-06-19 | 1997-09-02 | Wilk Patent Development Corp. | Coronary artery by-pass method |
US5666970A (en) * | 1995-05-02 | 1997-09-16 | Heart Rhythm Technologies, Inc. | Locking mechanism for catheters |
US5735897A (en) * | 1993-10-19 | 1998-04-07 | Scimed Life Systems, Inc. | Intravascular stent pump |
US5741330A (en) * | 1990-10-31 | 1998-04-21 | Baxter International, Inc. | Close vascularization implant material |
US5755682A (en) * | 1996-08-13 | 1998-05-26 | Heartstent Corporation | Method and apparatus for performing coronary artery bypass surgery |
US5756127A (en) * | 1996-10-29 | 1998-05-26 | Wright Medical Technology, Inc. | Implantable bioresorbable string of calcium sulfate beads |
US5769843A (en) * | 1996-02-20 | 1998-06-23 | Cormedica | Percutaneous endomyocardial revascularization |
US5782823A (en) * | 1996-04-05 | 1998-07-21 | Eclipse Surgical Technologies, Inc. | Laser device for transmyocardial revascularization procedures including means for enabling a formation of a pilot hole in the epicardium |
US5785702A (en) * | 1996-10-15 | 1998-07-28 | Eclipse Surgical Technologies, Inc. | Method for non-synchronous laser-assisted transmyocardial revascularization |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US5797870A (en) * | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
US5807384A (en) * | 1996-12-20 | 1998-09-15 | Eclipse Surgical Technologies, Inc. | Transmyocardial revascularization (TMR) enhanced treatment for coronary artery disease |
US5810836A (en) * | 1996-03-04 | 1998-09-22 | Myocardial Stents, Inc. | Device and method for trans myocardial revascularization (TMR) |
US5873499A (en) * | 1996-08-14 | 1999-02-23 | Scientific Resources, Inc. | Pressure breakaway dispensing gun |
US5925012A (en) * | 1996-12-27 | 1999-07-20 | Eclipse Surgical Technologies, Inc. | Laser assisted drug delivery |
US6045565A (en) * | 1997-11-04 | 2000-04-04 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization growth factor mediums and method |
US6263880B1 (en) * | 1998-06-22 | 2001-07-24 | Neovasys, Inc. | Method of enhancing blood flow in tissue |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1278965A (en) | 1961-01-27 | 1961-12-15 | Maison Drapier | Improvements to medical catheters |
FR1514319A (en) | 1967-01-11 | 1968-02-23 | Device for implantation in the apical region of the heart of an artificial ventricle | |
US3995617A (en) | 1972-05-31 | 1976-12-07 | Watkins David H | Heart assist method and catheter |
US3991750A (en) | 1975-04-28 | 1976-11-16 | Syntex Corporation | Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals |
US4307722A (en) | 1979-08-14 | 1981-12-29 | Evans Joseph M | Dilators for arterial dilation |
US4548206A (en) | 1983-07-21 | 1985-10-22 | Cook, Incorporated | Catheter wire guide with movable mandril |
FR2583985B1 (en) | 1985-06-27 | 1988-08-05 | Nivarox Sa | STYLET FOR ELECTRODE IMPLANTABLE IN THE BODY |
US4785815A (en) | 1985-10-23 | 1988-11-22 | Cordis Corporation | Apparatus for locating and ablating cardiac conduction pathways |
US5266073A (en) | 1987-12-08 | 1993-11-30 | Wall W Henry | Angioplasty stent |
US4917102A (en) | 1988-09-14 | 1990-04-17 | Advanced Cardiovascular Systems, Inc. | Guidewire assembly with steerable adjustable tip |
US5158548A (en) | 1990-04-25 | 1992-10-27 | Advanced Cardiovascular Systems, Inc. | Method and system for stent delivery |
US5172699A (en) | 1990-10-19 | 1992-12-22 | Angelase, Inc. | Process of identification of a ventricular tachycardia (VT) active site and an ablation catheter system |
US5562613A (en) | 1991-07-02 | 1996-10-08 | Intermed, Inc. | Subcutaneous drug delivery device |
US5256146A (en) | 1991-10-11 | 1993-10-26 | W. D. Ensminger | Vascular catheterization system with catheter anchoring feature |
US5269326A (en) | 1991-10-24 | 1993-12-14 | Georgetown University | Method for transvenously accessing the pericardial space via the right auricle for medical procedures |
US5167614A (en) | 1991-10-29 | 1992-12-01 | Medical Engineering Corporation | Prostatic stent |
US5372600A (en) | 1991-10-31 | 1994-12-13 | Instent Inc. | Stent delivery systems |
US5281197A (en) * | 1992-07-27 | 1994-01-25 | Symbiosis Corporation | Endoscopic hemostatic agent delivery system |
US5682906A (en) | 1993-02-22 | 1997-11-04 | Heartport, Inc. | Methods of performing intracardiac procedures on an arrested heart |
WO1994021308A1 (en) | 1993-03-18 | 1994-09-29 | Cedars-Sinai Medical Center | Drug incorporating and releasing polymeric coating for bioprosthesis |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5458615A (en) | 1993-07-06 | 1995-10-17 | Advanced Cardiovascular Systems, Inc. | Stent delivery system |
US5562619A (en) | 1993-08-19 | 1996-10-08 | Boston Scientific Corporation | Deflectable catheter |
US5464404A (en) | 1993-09-20 | 1995-11-07 | Abela Laser Systems, Inc. | Cardiac ablation catheters and method |
US5476505A (en) | 1993-11-18 | 1995-12-19 | Advanced Cardiovascular Systems, Inc. | Coiled stent and delivery system |
US5376071A (en) | 1993-11-19 | 1994-12-27 | Henderson; David D. | Intravenous catheter assembly and method of insertion |
EP0666065A1 (en) | 1994-02-02 | 1995-08-09 | Katsushi Mori | Stent for biliary, urinary or vascular system |
US5683345A (en) * | 1994-10-27 | 1997-11-04 | Novoste Corporation | Method and apparatus for treating a desired area in the vascular system of a patient |
US5614578A (en) | 1994-10-28 | 1997-03-25 | Alza Corporation | Injection-molded dosage form |
US5571168A (en) | 1995-04-05 | 1996-11-05 | Scimed Lifesystems Inc | Pull back stent delivery system |
US5840059A (en) | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
US5690643A (en) | 1996-02-20 | 1997-11-25 | Leocor, Incorporated | Stent delivery system |
US5971993A (en) | 1996-11-07 | 1999-10-26 | Myocardial Stents, Inc. | System for delivery of a trans myocardial device to a heart wall |
US5817101A (en) | 1997-03-13 | 1998-10-06 | Schneider (Usa) Inc | Fluid actuated stent delivery system |
US5980548A (en) | 1997-10-29 | 1999-11-09 | Kensey Nash Corporation | Transmyocardial revascularization system |
-
1997
- 1997-12-18 US US08/993,586 patent/US6251418B1/en not_active Expired - Fee Related
-
1998
- 1998-12-18 DE DE69831978T patent/DE69831978T2/en not_active Expired - Fee Related
- 1998-12-18 ES ES98966015T patent/ES2251123T3/en not_active Expired - Lifetime
- 1998-12-18 EP EP98966015A patent/EP1047471B1/en not_active Expired - Lifetime
- 1998-12-18 JP JP2000538740A patent/JP2002508227A/en not_active Withdrawn
- 1998-12-18 WO PCT/US1998/026977 patent/WO1999030764A1/en active IP Right Grant
-
2001
- 2001-06-25 US US09/888,757 patent/US20010033867A1/en not_active Abandoned
Patent Citations (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2269963A (en) * | 1940-06-01 | 1942-01-13 | Wappler Frederick Charles | Implanting device |
US2969963A (en) * | 1958-05-07 | 1961-01-31 | Brown Engine Products Inc | Carburetor |
US3680544A (en) * | 1970-09-09 | 1972-08-01 | James P Shinnick | Transthoracic cannula-type device for cardiopulmonary resuscitation |
US4588395A (en) * | 1978-03-10 | 1986-05-13 | Lemelson Jerome H | Catheter and method |
US4641653A (en) * | 1978-06-02 | 1987-02-10 | Rockey Arthur G | Medical sleeve |
US4457712A (en) * | 1979-11-13 | 1984-07-03 | Dragan William B | Dental syringe |
US4461280A (en) * | 1980-12-15 | 1984-07-24 | Baumgartner George C | Surgical instrument and process |
US4451253A (en) * | 1980-12-18 | 1984-05-29 | Harman Sherman M | Means and method for administering medicinals |
US4655771B1 (en) * | 1982-04-30 | 1996-09-10 | Medinvent Ams Sa | Prosthesis comprising an expansible or contractile tubular body |
US4655771A (en) * | 1982-04-30 | 1987-04-07 | Shepherd Patents S.A. | Prosthesis comprising an expansible or contractile tubular body |
US4562597A (en) * | 1982-12-13 | 1986-01-07 | Possis Medical, Inc. | Method of supplying blood to blood receiving vessels |
US4503569A (en) * | 1983-03-03 | 1985-03-12 | Dotter Charles T | Transluminally placed expandable graft prosthesis |
US4774949A (en) * | 1983-06-14 | 1988-10-04 | Fogarty Thomas J | Deflector guiding catheter |
US4582181A (en) * | 1983-08-12 | 1986-04-15 | Advanced Cardiovascular Systems, Inc. | Steerable dilatation catheter |
US4579061A (en) * | 1984-06-29 | 1986-04-01 | Rexnord Inc. | Spike driving machine including improved rail clamping apparatus |
US5114414A (en) * | 1984-09-18 | 1992-05-19 | Medtronic, Inc. | Low profile steerable catheter |
US4580568A (en) * | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
US4658817A (en) * | 1985-04-01 | 1987-04-21 | Children's Hospital Medical Center | Method and apparatus for transmyocardial revascularization using a laser |
US4718425A (en) * | 1985-05-29 | 1988-01-12 | Mitsui Toatsu Chemicals Incorporated | Catheter with pressure sensor |
US4733665B1 (en) * | 1985-11-07 | 1994-01-11 | Expandable Grafts Partnership | Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4681110A (en) * | 1985-12-02 | 1987-07-21 | Wiktor Dominik M | Catheter arrangement having a blood vessel liner, and method of using it |
US4700692A (en) * | 1985-12-23 | 1987-10-20 | Baumgartner George C | Surgical implantation method and apparatus |
US4665918A (en) * | 1986-01-06 | 1987-05-19 | Garza Gilbert A | Prosthesis system and method |
US4649922A (en) * | 1986-01-23 | 1987-03-17 | Wiktor Donimik M | Catheter arrangement having a variable diameter tip and spring prosthesis |
US4768507A (en) * | 1986-02-24 | 1988-09-06 | Medinnovations, Inc. | Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis |
US4852580A (en) * | 1986-09-17 | 1989-08-01 | Axiom Medical, Inc. | Catheter for measuring bioimpedance |
USRE34936E (en) * | 1986-10-06 | 1995-05-09 | Bio Medic Data Systems, Inc. | Animal marker implanting system |
US4861330A (en) * | 1987-03-12 | 1989-08-29 | Gene Voss | Cardiac assist device and method |
US4861336A (en) * | 1987-04-01 | 1989-08-29 | Helzel Manfred W | Puncture catheter |
US4813925A (en) * | 1987-04-21 | 1989-03-21 | Medical Engineering Corporation | Spiral ureteral stent |
US5098374A (en) * | 1987-09-02 | 1992-03-24 | Engineers & Doctors A/A | Device for the placing of a partial catheter in a body cavity |
US4920980A (en) * | 1987-09-14 | 1990-05-01 | Cordis Corporation | Catheter with controllable tip |
US5487739A (en) * | 1987-11-17 | 1996-01-30 | Brown University Research Foundation | Implantable therapy systems and methods |
US4950227A (en) * | 1988-11-07 | 1990-08-21 | Boston Scientific Corporation | Stent delivery system |
US4917666A (en) * | 1988-11-14 | 1990-04-17 | Medtronic Versaflex, Inc. | Steerable thru-lumen catheter |
US4909250A (en) * | 1988-11-14 | 1990-03-20 | Smith Joseph R | Implant system for animal identification |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US4995857A (en) * | 1989-04-07 | 1991-02-26 | Arnold John R | Left ventricular assist device and method for temporary and permanent procedures |
US5047028A (en) * | 1989-05-12 | 1991-09-10 | Quinghua Qian | Method for inducing thrombosis in blood vessels |
US5056517A (en) * | 1989-07-24 | 1991-10-15 | Consiglio Nazionale Delle Ricerche | Biomagnetically localizable multipurpose catheter and method for magnetocardiographic guided intracardiac mapping, biopsy and ablation of cardiac arrhythmias |
US4997431A (en) * | 1989-08-30 | 1991-03-05 | Angeion Corporation | Catheter |
US5042486A (en) * | 1989-09-29 | 1991-08-27 | Siemens Aktiengesellschaft | Catheter locatable with non-ionizing field and method for locating same |
US5049138A (en) * | 1989-11-13 | 1991-09-17 | Boston Scientific Corporation | Catheter with dissolvable tip |
US5322510A (en) * | 1989-11-21 | 1994-06-21 | Andreas Lindner | Injection apparatus |
US5342394A (en) * | 1990-05-16 | 1994-08-30 | Olympus Optical Co., Ltd. | Apparatus for blocking a vein branch and method of blocking a vein branch |
US5087243A (en) * | 1990-06-18 | 1992-02-11 | Boaz Avitall | Myocardial iontophoresis |
US5040543A (en) * | 1990-07-25 | 1991-08-20 | C. R. Bard, Inc. | Movable core guidewire |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5741330A (en) * | 1990-10-31 | 1998-04-21 | Baxter International, Inc. | Close vascularization implant material |
US5389096A (en) * | 1990-12-18 | 1995-02-14 | Advanced Cardiovascular Systems | System and method for percutaneous myocardial revascularization |
US5380316A (en) * | 1990-12-18 | 1995-01-10 | Advanced Cardiovascular Systems, Inc. | Method for intra-operative myocardial device revascularization |
US5312456A (en) * | 1991-01-31 | 1994-05-17 | Carnegie Mellon University | Micromechanical barb and method for making the same |
US5190058A (en) * | 1991-05-22 | 1993-03-02 | Medtronic, Inc. | Method of using a temporary stent catheter |
US5635215A (en) * | 1991-05-29 | 1997-06-03 | Biosepra S.A. | Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same |
US5324325A (en) * | 1991-06-27 | 1994-06-28 | Siemens Pacesetter, Inc. | Myocardial steroid releasing lead |
US5501664A (en) * | 1991-07-02 | 1996-03-26 | Intermed, Inc. | Subcutaneous drug delivery device |
US5551954A (en) * | 1991-10-04 | 1996-09-03 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5386828A (en) * | 1991-12-23 | 1995-02-07 | Sims Deltec, Inc. | Guide wire apparatus with location sensing member |
US5176626A (en) * | 1992-01-15 | 1993-01-05 | Wilson-Cook Medical, Inc. | Indwelling stent |
US5593434A (en) * | 1992-01-31 | 1997-01-14 | Advanced Cardiovascular Systems, Inc. | Stent capable of attachment within a body lumen |
US5423885A (en) * | 1992-01-31 | 1995-06-13 | Advanced Cardiovascular Systems, Inc. | Stent capable of attachment within a body lumen |
US5629008A (en) * | 1992-06-02 | 1997-05-13 | C.R. Bard, Inc. | Method and device for long-term delivery of drugs |
US5290295A (en) * | 1992-07-15 | 1994-03-01 | Querals & Fine, Inc. | Insertion tool for an intraluminal graft procedure |
US5618563A (en) * | 1992-09-10 | 1997-04-08 | Children's Medical Center Corporation | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
US5287861A (en) * | 1992-10-30 | 1994-02-22 | Wilk Peter J | Coronary artery by-pass method and associated catheter |
US5409019A (en) * | 1992-10-30 | 1995-04-25 | Wilk; Peter J. | Coronary artery by-pass method |
US5429144A (en) * | 1992-10-30 | 1995-07-04 | Wilk; Peter J. | Coronary artery by-pass method |
US5656029A (en) * | 1992-12-01 | 1997-08-12 | Cardiac Pathways Corporation | Steerable catheter with adjustable bend location and/or radius and method |
US5446499A (en) * | 1992-12-23 | 1995-08-29 | Daewoo Electronics Co., Inc. | Window signal generating apparatus |
US5452733A (en) * | 1993-02-22 | 1995-09-26 | Stanford Surgical Technologies, Inc. | Methods for performing thoracoscopic coronary artery bypass |
US5425757A (en) * | 1993-05-21 | 1995-06-20 | Tiefenbrun; Jonathan | Aortic surgical procedure |
US5409004A (en) * | 1993-06-11 | 1995-04-25 | Cook Incorporated | Localization device with radiopaque markings |
US5391199A (en) * | 1993-07-20 | 1995-02-21 | Biosense, Inc. | Apparatus and method for treating cardiac arrhythmias |
US5480422A (en) * | 1993-07-20 | 1996-01-02 | Biosense, Inc. | Apparatus for treating cardiac arrhythmias |
US5405376A (en) * | 1993-08-27 | 1995-04-11 | Medtronic, Inc. | Method and apparatus for ablation |
US5558091A (en) * | 1993-10-06 | 1996-09-24 | Biosense, Inc. | Magnetic determination of position and orientation |
US5735897A (en) * | 1993-10-19 | 1998-04-07 | Scimed Life Systems, Inc. | Intravascular stent pump |
US5602301A (en) * | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
US5593412A (en) * | 1994-03-01 | 1997-01-14 | Cordis Corporation | Stent delivery method and apparatus |
US5453090A (en) * | 1994-03-01 | 1995-09-26 | Cordis Corporation | Method of stent delivery through an elongate softenable sheath |
US5441516A (en) * | 1994-03-03 | 1995-08-15 | Scimed Lifesystems Inc. | Temporary stent |
US5514176A (en) * | 1995-01-20 | 1996-05-07 | Vance Products Inc. | Pull apart coil stent |
US5643308A (en) * | 1995-02-28 | 1997-07-01 | Markman; Barry Stephen | Method and apparatus for forming multiple cavities for placement of hair grafts |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
US5666970A (en) * | 1995-05-02 | 1997-09-16 | Heart Rhythm Technologies, Inc. | Locking mechanism for catheters |
US5797870A (en) * | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
US5769843A (en) * | 1996-02-20 | 1998-06-23 | Cormedica | Percutaneous endomyocardial revascularization |
US5810836A (en) * | 1996-03-04 | 1998-09-22 | Myocardial Stents, Inc. | Device and method for trans myocardial revascularization (TMR) |
US5782823A (en) * | 1996-04-05 | 1998-07-21 | Eclipse Surgical Technologies, Inc. | Laser device for transmyocardial revascularization procedures including means for enabling a formation of a pilot hole in the epicardium |
US5662124A (en) * | 1996-06-19 | 1997-09-02 | Wilk Patent Development Corp. | Coronary artery by-pass method |
US5755682A (en) * | 1996-08-13 | 1998-05-26 | Heartstent Corporation | Method and apparatus for performing coronary artery bypass surgery |
US5873499A (en) * | 1996-08-14 | 1999-02-23 | Scientific Resources, Inc. | Pressure breakaway dispensing gun |
US5655548A (en) * | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
US5785702A (en) * | 1996-10-15 | 1998-07-28 | Eclipse Surgical Technologies, Inc. | Method for non-synchronous laser-assisted transmyocardial revascularization |
US5756127A (en) * | 1996-10-29 | 1998-05-26 | Wright Medical Technology, Inc. | Implantable bioresorbable string of calcium sulfate beads |
US5807384A (en) * | 1996-12-20 | 1998-09-15 | Eclipse Surgical Technologies, Inc. | Transmyocardial revascularization (TMR) enhanced treatment for coronary artery disease |
US5925012A (en) * | 1996-12-27 | 1999-07-20 | Eclipse Surgical Technologies, Inc. | Laser assisted drug delivery |
US6045565A (en) * | 1997-11-04 | 2000-04-04 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization growth factor mediums and method |
US6263880B1 (en) * | 1998-06-22 | 2001-07-24 | Neovasys, Inc. | Method of enhancing blood flow in tissue |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090131825A1 (en) * | 1999-02-02 | 2009-05-21 | Senorx, Inc. | Imageable biopsy site marker |
US20050143656A1 (en) * | 1999-02-02 | 2005-06-30 | Senorx, Inc. | Cavity-filling biopsy site markers |
US8965486B2 (en) | 1999-02-02 | 2015-02-24 | Senorx, Inc. | Cavity filling biopsy site markers |
US8219182B2 (en) | 1999-02-02 | 2012-07-10 | Senorx, Inc. | Cavity-filling biopsy site markers |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US20060084865A1 (en) * | 1999-02-02 | 2006-04-20 | Burbank Fred H | Imageable biopsy site marker |
US9861294B2 (en) | 1999-02-02 | 2018-01-09 | Senorx, Inc. | Marker delivery device with releasable plug |
US8626270B2 (en) | 1999-02-02 | 2014-01-07 | Senorx, Inc. | Cavity-filling biopsy site markers |
US10172674B2 (en) | 1999-02-02 | 2019-01-08 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US9649093B2 (en) | 1999-02-02 | 2017-05-16 | Senorx, Inc. | Cavity-filling biopsy site markers |
US7792569B2 (en) | 1999-02-02 | 2010-09-07 | Senorx, Inc. | Cavity-filling biopsy site markers |
US9237937B2 (en) | 1999-02-02 | 2016-01-19 | Senorx, Inc. | Cavity-filling biopsy site markers |
US9149341B2 (en) | 1999-02-02 | 2015-10-06 | Senorx, Inc | Deployment of polysaccharide markers for treating a site within a patient |
US9044162B2 (en) | 1999-02-02 | 2015-06-02 | Senorx, Inc. | Marker delivery device with releasable plug |
US20160279200A1 (en) * | 2001-04-27 | 2016-09-29 | Cormend Technologies, Llc | Prevention of myocardial infarction induced ventricular expansion and remodeling |
US9931375B2 (en) * | 2001-04-27 | 2018-04-03 | Cormend Technologies, Llc | Prevention of myocardial infarction induced ventricular expansion and remodeling |
US7651505B2 (en) | 2002-06-17 | 2010-01-26 | Senorx, Inc. | Plugged tip delivery for marker placement |
US8784433B2 (en) | 2002-06-17 | 2014-07-22 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US8177792B2 (en) | 2002-06-17 | 2012-05-15 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
WO2003105940A2 (en) | 2002-06-17 | 2003-12-24 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
WO2003105940A3 (en) * | 2002-06-17 | 2004-04-22 | Senorx Inc | Plugged tip delivery tube for marker placement |
US8639315B2 (en) | 2003-05-23 | 2014-01-28 | Senorx, Inc. | Marker or filler forming fluid |
US9801688B2 (en) | 2003-05-23 | 2017-10-31 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US8447386B2 (en) | 2003-05-23 | 2013-05-21 | Senorx, Inc. | Marker or filler forming fluid |
US10299881B2 (en) | 2003-05-23 | 2019-05-28 | Senorx, Inc. | Marker or filler forming fluid |
US20040236213A1 (en) * | 2003-05-23 | 2004-11-25 | Senorx, Inc. | Marker delivery device with releasable plug |
US8880154B2 (en) | 2003-05-23 | 2014-11-04 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US10045832B2 (en) | 2003-05-23 | 2018-08-14 | Senorx, Inc. | Marker or filler forming fluid |
US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US7970454B2 (en) | 2003-05-23 | 2011-06-28 | Senorx, Inc. | Marker delivery device with releasable plug |
US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
US20050119562A1 (en) * | 2003-05-23 | 2005-06-02 | Senorx, Inc. | Fibrous marker formed of synthetic polymer strands |
US8626269B2 (en) | 2003-05-23 | 2014-01-07 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US20090287078A1 (en) * | 2003-05-23 | 2009-11-19 | Senorx, Inc. | Marker or filler forming fluid |
US20080058640A1 (en) * | 2006-08-04 | 2008-03-06 | Senoxrx, Inc. | Marker formed of starch or other suitable polysaccharide |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
WO2012126000A2 (en) * | 2011-03-17 | 2012-09-20 | Emory University | Delivery devices and methods for delivering therapeutic agents |
WO2012126000A3 (en) * | 2011-03-17 | 2013-01-03 | Emory University | Delivery devices and methods for delivering therapeutic agents |
US20140180065A1 (en) * | 2011-05-11 | 2014-06-26 | The Regents Of The University Of California | Fiduciary markers and methods of placement |
US9414752B2 (en) | 2012-11-09 | 2016-08-16 | Elwha Llc | Embolism deflector |
US9295393B2 (en) | 2012-11-09 | 2016-03-29 | Elwha Llc | Embolism deflector |
US10384048B2 (en) | 2014-07-25 | 2019-08-20 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having an occluding member |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US10478603B2 (en) | 2014-07-25 | 2019-11-19 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US11464958B2 (en) | 2014-07-25 | 2022-10-11 | Warsaw Orthopedic, Inc. | Drug delivery methods having an occluding member |
US11504513B2 (en) | 2014-07-25 | 2022-11-22 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US11759614B2 (en) | 2015-11-23 | 2023-09-19 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
US10549081B2 (en) | 2016-06-23 | 2020-02-04 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US11413442B2 (en) | 2016-06-23 | 2022-08-16 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US11478587B2 (en) | 2016-11-08 | 2022-10-25 | Warsaw Orthopedic, Inc. | Drug depot delivery system and method |
Also Published As
Publication number | Publication date |
---|---|
US6251418B1 (en) | 2001-06-26 |
EP1047471A1 (en) | 2000-11-02 |
ES2251123T3 (en) | 2006-04-16 |
DE69831978T2 (en) | 2006-07-27 |
WO1999030764A1 (en) | 1999-06-24 |
DE69831978D1 (en) | 2006-03-02 |
JP2002508227A (en) | 2002-03-19 |
EP1047471B1 (en) | 2005-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6251418B1 (en) | Systems and methods for local delivery of an agent | |
EP1518549B1 (en) | A pellet comprising a local anesthetic agent and a radiopaque material | |
EP1484081B1 (en) | System for treating ischemia | |
US6322548B1 (en) | Delivery catheter system for heart chamber | |
US5997509A (en) | Minimally invasive gene therapy delivery device and method | |
US8529550B2 (en) | Implant delivery catheter system and methods for its use | |
US6416510B1 (en) | Drug delivery catheters that attach to tissue and methods for their use | |
US6554794B1 (en) | Non-deforming deflectable multi-lumen catheter | |
US6547787B1 (en) | Drug delivery catheters that attach to tissue and methods for their use | |
EP1307254B1 (en) | Controlled depth injection device and method | |
US20150290428A1 (en) | Catheter for introduction of medications to the tissues of a heart or other organ | |
US6723082B1 (en) | Delivery catheter system for heart chamber | |
EP1588731B1 (en) | Local drug delivery catheter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |